University of Pennsylvania

ScholarlyCommons
Publicly Accessible Penn Dissertations
2022

User-Friendly, Low-Cost, Microfluidic Devices With Capillary
Circuits For Multiplexed, Isothermal, Point-Of-Care, Nucleic Acid
Amplification Tests
Huiwen Bai
University of Pennsylvania

Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Mechanical Engineering Commons

Recommended Citation
Bai, Huiwen, "User-Friendly, Low-Cost, Microfluidic Devices With Capillary Circuits For Multiplexed,
Isothermal, Point-Of-Care, Nucleic Acid Amplification Tests" (2022). Publicly Accessible Penn
Dissertations. 5504.
https://repository.upenn.edu/edissertations/5504

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/5504
For more information, please contact repository@pobox.upenn.edu.

User-Friendly, Low-Cost, Microfluidic Devices With Capillary Circuits For
Multiplexed, Isothermal, Point-Of-Care, Nucleic Acid Amplification Tests
Abstract
Rapid, sensitive, and specific detection of causative pathogens is key to personalized medicine and the
prompt implementation of appropriate mitigation measures to reduce disease transmission, mortality,
morbidity, and cost. Conventional molecular detection methods require trained personnel, sophisticated
equipment, and specialized laboratories, which limits their use to centralized laboratories. To enable
molecular diagnostics at the point of need and in resource-poor settings, inexpensive, simple devices that
combine multiple unit operations and are capable of co-detecting endemic pathogens are needed.
In this work, I have developed microfluidic devices with capillary circuits to automate liquid distribution,
eliminating the need for expensive equipment, sophisticated laboratory facilities, and skilled personnel to
enable molecular diagnostics at the point of need. Capillary valves with different sizes were developed
and implemented to aliquot samples and reagents to multiple reaction chambers and to enable draining
liquids from supply lines without affecting liquids in the various reaction chambers, enabling bubble-free
operation. The sealing of my microfluidic devices to prevent evaporation during incubation is facilitated
with phase-change materials and capillary-induced motion. When my microfluidic chip is heated to its
incubation temperature, the phase-change material melts and flows to seal ports of entry and air vent.
Numerical simulations were carried out to assess the viability of on-chip, in-house developed, two-stage
isothermal nucleic acid amplification in the presence of diffusion and advection. An Android-based
smartphone application was developed to automate real-time signal monitoring, time series image
analysis, and diagnostic result interpretation. Three 3D-printed, portable, microfluidic devices with
capillary circuits were designed, fabricated, and tested for single-stage and two-stage, isothermal nucleic
acid amplification with either liquid reagents or pre-stored dry reagents that do not require a cold chain.
All devices have proved successful for rapid, sensitive, and specific multiplexed detections of human and
animal pathogens.
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ABSTRACT
USER-FRIENDLY, LOW-COST, MICROFLUIDIC DEVICES WITH CAPILLARY CIRCUITS FOR
MULTIPLEXED, ISOTHERMAL, POINT-OF-CARE, NUCLEIC ACID AMPLIFICATION TESTS
Huiwen Bai
Haim H. Bau
Rapid, sensitive, and specific detection of causative pathogens is key to personalized medicine
and the prompt implementation of appropriate mitigation measures to reduce disease
transmission, mortality, morbidity, and cost. Conventional molecular detection methods require
trained personnel, sophisticated equipment, and specialized laboratories, which limits their use to
centralized laboratories. To enable molecular diagnostics at the point of need and in resourcepoor settings, inexpensive, simple devices that combine multiple unit operations and are capable
of co-detecting endemic pathogens are needed.
In this work, I have developed microfluidic devices with capillary circuits to automate
liquid distribution, eliminating the need for expensive equipment, sophisticated laboratory
facilities, and skilled personnel to enable molecular diagnostics at the point of need. Capillary
valves with different sizes were developed and implemented to aliquot samples and reagents to
multiple reaction chambers and to enable draining liquids from supply lines without affecting
liquids in the various reaction chambers, enabling bubble-free operation. The sealing of my
microfluidic devices to prevent evaporation during incubation is facilitated with phase-change
materials and capillary-induced motion. When my microfluidic chip is heated to its incubation
temperature, the phase-change material melts and flows to seal ports of entry and air vent.
Numerical simulations were carried out to assess the viability of on-chip, in-house developed,
two-stage isothermal nucleic acid amplification in the presence of diffusion and advection. An
Android-based smartphone application was developed to automate real-time signal monitoring,
time series image analysis, and diagnostic result interpretation. Three 3D-printed, portable,
microfluidic devices with capillary circuits were designed, fabricated, and tested for single-stage
and two-stage, isothermal nucleic acid amplification with either liquid reagents or pre-stored dry
iv

reagents that do not require a cold chain. All devices have proved successful for rapid, sensitive,
and specific multiplexed detections of human and animal pathogens.
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Chapter 1 Introduction
1.1 Microfluidics in Point-of-care (POC) Nucleic-acid Amplification Tests (NAATs)
Rapid, sensitive, and specific detection of biomarkers associated with diseases is key to the
prompt implementation of therapeutics and mitigation measures to reduce disease transmission,
thereby reducing morbidity, mortality, and cost. For example, the COVID-19 outbreak has
introduced significant challenges to global health and dramatically changed the lives of everyone.
This outbreak has claimed millions of lives worldwide and caused substantial economic losses.
As new variants continue to emerge, the negative impacts brought by this pandemic have not yet
come to an end. The availability of sensitive and rapid tests for SARS-Cov-2 is an essential tool in
the effort to minimize the spread of this disease.
Nucleic-acid amplification tests (NAATs) and antigen tests are two types of commonly used
diagnostic tests. Compared to antigen tests, NAATs offer higher sensitivity and specificity and an
earlier detection window prior to seroconversion. Standard NAATs require trained personnel and
specialized equipment that are only available within centralized laboratories, prolonging the time
from sample collection to results. In resource-limited settings, and especially in less-developed
countries, few centralized laboratories are available, and the turnaround times for NAATs may
take up to a few days. Point-of-care testing (POCT) refers to the diagnostic tests performed near
the patient outside of centralized laboratories, which eliminates the need for sending samples to
the lab and therefore reduces turnaround times.
Microfluidics is the technology of fluid manipulation at the microscale and has been proved
effective for POCT, including molecular detection [1-9]. Microfluidics has a number of advantages
for POCT such as (1) small reagent volumes, reducing reagent costs, (2) small sample volumes,
(3) miniaturization that makes it possible to integrate multiple unit operations onto a single chip,
improving portability, (4) amenability for multiplexing that allows performing multiple diagnostic
tests for different targets in parallel, and (5) comparable sensitivity and specificity to laboratorybased tests. Overall, currently used microfluidic devices offer relatively low-cost and portable
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solutions to POC NAATs but still require trained personnel and some laboratory equipment such
as syringe pumps and pipettes for reliable fluid control.
My Ph.D. research focuses on reducing diagnostic cost and operational complexity by
developing microfluidic devices for rapid POC NAATs that are affordable and user-friendly for
resource-poor settings while maintaining the same level of sensitivity and specificity as
laboratory-based tests.

1.2 Isothermal Nucleic-acid Amplification Tests (NAATs)
Isothermal NAATs have many distinct advantages for POCT over the laboratory-based PCR that
requires thermal cycling. Most importantly, isothermal reaction simplifies the design complexity
and reduces the cost of heating/incubation systems. Incubation can even be carried out
electricity-free with chemical heating regulated by phase-change materials (PCMs) [5, 10]. Our
group has developed a two-stage isothermal nucleic acid amplification assay dubbed Penn
RAMP that combines two isothermal amplification processes - recombinase polymerase
amplification (RPA) and loop-mediated isothermal amplification (LAMP) [11, 12] to enable
extensive multiplexing and higher sensitivity than can be obtained with a single-stage process.
Isothermal NAATs were adopted in all the devices discussed in this thesis.

1.3 Capillary Circuits
A typical microfluidic setup for isothermal NAATs consists of a microfluidic chip with miniaturized
unit operations, syringe pumps and pipettes to provide precise fluid control, a microscope to
monitor the amplification process, and a heating system for incubation. An inexpensive
homemade heating system meets the requirement of isothermal NAATs, and a smartphone can
be used to replace microscopes to monitor amplification. A simple method of flow control is still
needed to replace syringe pumps.
Capillary circuits are the combination of capillary “pumps” and valves that regulate fluid
flow on chip with capillary forces. Different from mechanical pumps and valves powered by
external driving forces, capillary pumps and valves rely on surface tension, materials’ wettability,
2

and microchannels' geometry. By judicious selection of materials with desired wettability and by
properly designing microchannels’ geometries, a capillary circuit can be formed to achieve
spontaneous, complex liquid distribution on chip. Compared to mechanical pumps and valves that
require movable components such as flexible membranes, capillary pumps and valves offer
simpler design and lower manufacturing complexity.
To understand the working principle of capillary circuits, the concepts of contact angle,
surface tension, and capillary pressure need to be discussed. The contact angle is the equilibrium
angle formed between the liquid-vapor interface and the solid surface (on the liquid’s side) at the
contact line. The relationship is quantitatively described by the Young equation
𝛾#$ cos 𝜃 + 𝛾#% = 𝛾%$ ,

(1.1)

where 𝜃 is the static contact angle measured between the tangent line of the liquid-vapor
interface and the solid substrate. 𝛾#$ , 𝛾#% and 𝛾%$ are, respectively, the surface energies of the
liquid-vapor, liquid-solid, and solid-vapor interfaces. Since 𝛾#$ , 𝛾#% and 𝛾%$ are material properties,
the static contact angle is constant for a given set of materials at a given temperature and
pressure. Across the curved liquid-vapor interface, there is a capillary pressure jump Δ𝑝" that can
be described by the Young-Laplace equation
1
1
Δ𝑝" = −𝛾 ; + = ,
𝑅& 𝑅'

(1.2)

where 𝑅& and 𝑅' are the principal radii of the liquid-vapor interface’s curvature. The capillary
pressure for a microfluidic channel with a rectangular cross-section can be approximated with the
following equation [13]
cos 𝜃( + cos 𝜃) cos 𝜃# + cos 𝜃*
𝑝" = 𝛾 ;
+
=,
𝐻
𝑊

(1.3)

where 𝐻 is the height and 𝑊 is the width of the microchannel’s cross-section, and 𝜃( , 𝜃) , 𝜃# , 𝜃* are
the contact angles formed with the upper, bottom, left, and right channel walls, respectively. For a
microchannel with a circular cross-section, the capillary pressure is described with the following
equation
𝑝" =

2𝛾 cos 𝜃
,
𝑟
3

(1.4)

where 𝑟 is the radius of the microchannel and 𝜃 is the contact angle. Equations 1.3 and 1.4 show
that the magnitude of capillary pressure is inversely proportional to the characteristic dimension of
the microchannel, which makes it more favorable for the microfluidic format.
A substrate with a static water contact angle smaller than 90° is considered hydrophilic,
while materials with static water contact angles larger than 90° are hydrophobic. When a
hydrophilic glass capillary tube is placed vertically into a water reservoir, a concave meniscus will
be formed and the hydraulic pressure near the liquid-vapor interface will be smaller than the
atmospheric pressure. Since the hydraulic pressure at the tube’s bottom is equal to or greater
than the atmospheric pressure, water will imbibe into the glass capillary until the capillary force is
balanced by the weight of the liquid column inside the glass capillary. This phenomenon is called
capillary suction and explains the working principle of capillary pumps.
To better understand the theories for capillary valves, it is essential to discuss contact
line motion and contact angle hysteresis. The contact line is the intersection line of liquid-vapor,
liquid-solid, and solid-vapor interfaces. Consider a case that water is slowly added into a water
droplet that sits on a smooth substrate. Initially, the contact line stays still, and the contact angle
increases until a critical value is reached. Then, the contact line advances. This critical contact
angle 𝜃+ is called the advancing contact angle. Similarly, when water is slowly removed from a
stationary water drop, which can be done with either evaporation or aspirating liquids with a
pipette, the contact line remains static until the receding contact angle 𝜃, is formed, at which time
the contact angle recedes. Transforming the contact angle from the equilibrium contact angle to
either the advancing or receding contact angle requires energy. The contact angle hysteresis the difference between the advancing and receding contact angles - describes the need for
activation energy to trigger the contact line motion [14].
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Fig. 1.1: Working principle of a capillary valve: The capillary valve is defined as the abrupt
dimension enlargement in a microchannel. A) The critical state of the meniscus when the
advancing contact line is halted by the capillary valve. B) The critical state of the meniscus when
the liquid is about to bridge the capillary valve. 𝜃& and 𝜃' are critical advancing contact angles
with respect to the horizontal and vertical wall, respectively.

Based on the notions of contact line motion and contact angle hysteresis, the advancing
angle is required for a liquid to propagate along a microchannel. A capillary valve is formed in the
presence of an abrupt enlargement of the conduit’s cross-section. Consider a hydrophilic
microchannel with the shape illustrated in Fig. 1.1 with a water inlet on the left. Water will flow into
the channel spontaneously driven by the negative Laplace pressure beneath the concave liquidair interface until the meniscus reaches the location of the abrupt change in the cross-section
dimensions (capillary valve, Fig. 1.1A), at which point the contact line is pinned. To move beyond
the enlargement in the cross-section, the meniscus must assume a convex shape with a positive
Laplace pressure (Fig. 1.1B). The pressure needed to reverse the meniscus from concave to
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convex in a capillary with radius 𝑟, when the entire structure is made of the same material, can be
expressed as
Δ𝑝 =

2𝛾
(cos 𝜃& + sin 𝜃' ),
𝑟

(1.5)

𝜃& and 𝜃' are critical advancing contact angles with respect to the horizontal and vertical wall,
respectively. Equation 1.5 illustrates that the maximum pressure a capillary valve can sustain is
inversely proportional to the channel’s radius 𝑟.

1.4 3D-printed Microfluidics
Over the past two decades, the fabrication method of microfluidics has been dominated by soft
lithography, micromachining, and injection molding, which are now challenged by rapidly
developing 3D printing technologies [15, 16]. 3D printing refers to various additive-based, rapid
prototyping techniques. Stereolithography (SLA) is the most widely used 3D printing technique to
manufacture microfluidic chips with enclosed channels [17] and was adopted to fabricate all the
devices discussed in this thesis.
Compared to conventional manufacturing methods, the 3D printing technique has the
following advantages. First, 3D printers are inexpensive and highly automated. There are many
inexpensive resin 3D printers (Phrozen Sonic Mini, Phrozen Technology, Taiwan, China;
Anycubic Photon Mono X, Anycubic Photon, Shenzhen, China; Formlabs Form 3, Formlabs,
Somerville, MA) commercially available that provide fair enough printing resolutions (e.g.,
Formlabs Form 3 offers 25-micron resolution in both the XY plane and the Z direction) to fabricate
microfluidic chips. The printers accept files in standardized formats and provide a one-button
start. Second, 3D printing manufactures complex 3D structures with short turnaround times.
Depending on the dimension of a microfluidic chip, a typical turnaround time for 3D printing is
usually hours while it may take up to days for soft lithography and milling and weeks for injection
modeling [18]. Third, the biocompatibility of 3D printed devices is well established and is
comparable to benchtop equipment [6].
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1.5 Microfluidics Chips for Molecular Detection
Over the past two decades, the development of microfluidic devices has proved successful for
molecular detection. The previously reported microfluidic devices can be categorized, based on
their approaches to fluid manipulation, into conventional microfluidics [5, 6, 11, 19-25], paperbased microfluidics [26-28], Lab-on-a-disc (LoD) microfluidics [29-31], and droplet-based
microfluidics [32, 33]. The Lab-on-a-disc (centrifugal) microfluidic system requires a rotational
system that controls the liquid flow with centrifugal, Euler, and Coriolis forces combined with onchip valving techniques [29]. The droplet-based microfluidics needs flow-focusing geometry and
fluid velocity control to produce uniform droplets [34]. Different from the two above-mentioned
types that require velocity control, the control requirement of the conventional microfluidic is on
the volume level, which is easier to be achieved. A conventional microfluidic device usually
requires a fixed volume of reagents to be loaded into the corresponding chamber on chip, which
can be satisfied with pipetting [11, 21]. Different from the other types of devices that usually
require pumping systems, the paper-based microfluidic devices are pump-free, reducing the
complexity of the systems’ design and operation [35]. The operational complexity and device cost
have an order of paper-based < conventional < Lab-on-a-disk and droplet-based [35], while the
complexity of fluid flow that can be achieved has a reversed order. Considering the complexity of
fluid distribution required by implementing Penn RAMP in a microfluidic format, our group focuses
on developing conventional microfluidic devices to pursue cost-effectiveness and userfriendliness. In this section, we review three representative works in the field of interest and
explain how our studies further improve the robustness, cost-effectiveness, and usability of
conventional microfluidic devices for molecular detection.
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Fig. 1.2: Illustration of the chip design and fluorescence image during NA amplification [11].

Song [11] developed a microfluidic chip for Penn RAMP. The chip comprises one RPA
and four LAMP chambers for multiplexed detection. The four identical LAMP chambers connect
to the RPA chamber on one end and to four independent inlets on the other end. The chip is
made of three CNC machined polymethyl methacrylate (PMMA) layers and assembled with
acetonitrile bonding. Prior to the two-stage amplification, LAMP solutions are first pipetted into
each LAMP chamber one by one. Next, the surfaces around the four LAMP inlets are thoroughly
dried. The LAMP inlets are then sealed with a PCR tape to prevent the solution from leaving
LAMP reactors when filling the RPA chamber. Last, the same loading, drying, and sealing
operations are repeated for the common RPA chamber. Overall, this chip (Fig. 1.2) successfully
demonstrates Penn-RAMP in a microfluidic format. However, this chip lacks the internal control of
fluid flow, and the chip operation requires multiple manual operations, risking severe
consequences due to potential operational errors. For example, when the LAMP solution is
accidentally overloaded, the excess LAMP solution will immediately flow into the RPA chamber
and eventually penetrate into other LAMP reactors. Since the LAMP solution in each LAMP
8

chamber contains a unique primer set corresponding to a specific target, the overload can
introduce cross-contamination of primers and eventually present false positives. In another case
when LAMP solutions are accidentally removed when drying the surface around the LAMP inlets,
the recession of LAMP solutions will introduce air bubbles between RPA and LAMP chambers
and cut off the connection between RPA and LAMP chambers. Besides the risks of malfunction,
there is also an opportunity to simplify the chip operation where the same LAMP loading is
repeated four times via four separate inlets.
Kadimisetty [6] reported a fully 3D-printed microfluidic chip with four independent reactors
that can perform multiple LAMP amplifications in parallel. The chip is fabricated with an
inexpensive 3D printer (Formlab Form 2, Formlabs, Somerville, MA) in two parts (Fig. 1.3),
enabling the insertion of nucleic acid isolation membranes (Qiagen Silica) into the chip. The inner
surface of the chip is treated with PEG for improved biocompatibility. The chip can perform both
NA isolation and amplification. During NA isolation, sample solutions and washing buffers are
sequentially pipetted into the chip through the inlets, pass through the nucleic acid isolation
membrane, and leave the chip via the outlets. The same sequence of operations is repeated for
each LAMP reactor. For NA amplification, LAMP solutions are pipetted into the chip, and all ports
(inlets and outlets) are then dried and sealed with a PCR tape [6]. Overall, Kadimisetty’s work is a
successful demonstration of 3D-printed microfluidics for a single-stage isothermal NAAT and has
proved the biocompatibility of the 3D printed material. However, similar to Song’s work [11], the
chip operation of Kadimisetty’s design lacks built-in controls, requiring manual operations to
provide fluid control, and the whole operation procedure needs to be repeated for each reactor to
achieve multiplexing.
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Fig. 1.3: Assembly of the chip with 3D printing [6].

Fig. 1.4: Detailed chip design. (A) Exploded view. (B) Pressure sealing component. (C)
Multiplexed reactors [9].

In a recently published paper, Zhong [9] developed a microfluidic system with up to
eighteen LAMP reactors for single-stage NAATs. The chip is manufactured with polycarbonate
10

(PC) substrate by injection molding. Hydrophobic membranes combined with pipetting are used
to provide on-chip fluid control. After loading the chip with a pipette, buckles are pushed down to
provide sealing (Fig. 1.4). The key innovation of Zhong’s work is to simplify operational
complexity, allowing the filling of multiple reaction chambers with a single loading step and
developing a user-friendly sealing method. However, to achieve one-stage loading, all reactors
are connected to the inlet and therefore are interconnected with each other. The crosscommunication among reactors is unavoidable but can be delayed by increasing the distances
between adjacent reactors. Additionally, like the devices discussed above [6, 11], pipettes are still
needed to load the sample.
We developed user-friendly, low-cost microfluidic devices with capillary circuits for
multiplexed NAATs. First, the fluid flow on chip is spontaneously driven by capillary forces and
regulated by capillary valves, eliminating the need for external instruments such as syringe
pumps. This both automates the liquid distribution on chip, enabling untrained personnel to
perform POC NAATs, and reduces the device’s cost, making it affordable for eventual home use.
Second, we developed means to pre-dry primers in individual reaction chambers during chip
manufacturing, enabling us to fill the chip with a universal reaction mix and avoiding the need to
fill individual reaction chambers separately. Third, we developed a method to drain the common
distribution channel, eliminating the risk of cross-contamination. Fourth, we automated the sealing
step with the use of phase-change materials (PCMs) that melt when the chip temperature is
increased to its incubation value, cover the inlet and exit ports to provide evaporation barriers
during incubation, and solidify after the conclusion of amplification to tomb the reaction products,
preventing them from contaminating the workspace. Fifth, we developed an Android-based
smartphone application for real-time signal monitoring and image analysis. Sixth, our devices are
fully 3D-printed can be easily reproduced with an inexpensive 3D printer that is commonly
available.
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1.6 Organization of the Dissertation
Chapter two describes a 3D-printed microfluidic device with capillary circuits for multiplexed
reverse-transcription loop-mediated isothermal amplification (RT-LAMP). The chip comprises four
LAMP reactors, each with a unique primer set for a specific target. The liquid distribution on chip
is controlled by capillary forces without reliance on external instruments. An innovative draining
process is used to remove excess liquids in connecting channels while LAMP reaction mixes in
the various reactors remain intact. The draining process isolates individual LAMP reactors and
prevents cross-contamination. Additionally, we adopted a thermally actuated sealing with phasechange materials (PCMs). The chip has proved successful for multiplexed detection of pig viruses
[36].
Chapter three adapts the design of the chip described in chapter two to accommodate the
storage of in-situ dried reagents and colorimetric detection. Pre-storage of dried LAMP reagents
on chip allows room temperature storage, while a standard liquid form of LAMP mix requires
storage at -20 °C. The colorimetric detection method enables reading diagnostic results by the
naked eye, which further reduces cost by eliminating the need for a fluorescence camera. An
Android-based smartphone application was developed for real-time signal monitoring and
automated image analysis. These are important steps toward a fully instrument-free multiplexed
LAMP in a microfluidic format for untrained personnel. The chip has proved successful for
multiplexed detection of human immunodeficiency virus and human hepatitis viruses.
Chapter four discusses a microfluidic device with more complicated capillary circuits for the
two-stage isothermal NAAT Penn RAMP that combines RPA and LAMP to achieve a higher level
of multiplexing and sensitivity. The chip consists of one RPA chamber connected with four LAMP
reactors. The biggest challenge we faced was distributing first-stage amplicons into multiple
second-stage reactors evenly. A numerical simulation of Penn RAMP was developed to guide
chip design, estimating the efficiency of first-stage amplicon distribution and potential crosscontamination. The chip has proved successful in implementing Penn RAMP on chip, and the onchip Penn RAMP has proved more sensitive for the detection of chicken infectious
laryngotracheitis virus compared to the standalone LAMP assay.
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Chapter five concludes the thesis.
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Chapter 2 Auto-distribution and Auto-sealing based on Capillary Circuits for
Single-stage NAATs
2.1 Introduction
In this chapter, we introduce a low-cost, rapid, semi-quantitative, field-deployable, 3D-printed
microfluidic device for auto-distribution of samples and self-sealing for real-time reverse
transcription-loop-mediated isothermal amplification (RT-LAMP), enabling the co-detection of the
porcine epidemic diarrhea virus (PEDV), transmissible gastroenteritis virus (TGEV), and porcine
deltacoronavirus (PDCoV) at the point of need within 30 minutes.
The Coronaviridae family of the Nidovirales order comprises four genera:
Alphacoronavirus, Betacoronavirus, Gammacoronavirus, and Deltacoronavirus. The porcine
epidemic diarrhea virus (PEDV) and transmissible gastroenteritis virus (TGEV) are members of
the Alphacoronavirus genus, while the porcine deltacoronavirus (PDCoV) is a Deltacoronavirus
[1]. Coronaviruses are positive-sense, single-stranded, enveloped RNA viruses and have an RNA
genome of 25-30 kb (kilobases), the largest ever reported. The virion RNA contains 5' and 3'
untranslated regions (UTRs), capped at the 5' end and polyadenylated at the 3' end. The 5'terminal two-thirds of the genome contain open reading frames (ORFs) 1a and 1ab that encode
two replicase polyproteins (pp1a and pp1ab). The 3'-terminal one-third of the genome encodes
structural proteins, including spike (S), envelope (E), membrane (M), and nucleocapsid (N)
proteins [2, 3].
PEDV, TGEV, and PDCoV are emerging/reemerging coronaviruses (CoVs) of neonatal
pigs and cause great economic losses to the pig industry [4]. All three viruses affect the animals’
enteric system, are antigenically distinct, lack cross-immunity protection, and cause acute
gastroenteritis in neonatal piglets with similar clinical manifestations. Infected intestinal epithelial
cells necrosis causes atrophy of the intestinal villi, diarrhea, growth retardation, dehydration, and
death of piglets [1, 5]. Currently, among these three viral infections, the PEDV infection is the
most significant and consequential in the USA. This is likely because PEDV has been only
recently introduced to the USA, and pigs in the USA lack immunity against it [4].
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Effective prevention and control of these diseases can be achieved by stringent
biosecurity measures, disease containment within and among farms, and vaccination. Vaccines
are available against TGEV and PEDV [1, 2, 6]. Rapid co-detection of these viruses would be
followed by rapid initiation of appropriate control measures, reducing the expected economic
losses.
Currently, confirmative diagnosis of these diseases is performed in centralized
laboratories by the enzyme-linked immunosorbent assay (ELISA), virus isolation, virus
neutralization (VN) and immunofluorescence techniques, quantitative real-time-reverse
transcription-PCR (qRT-PCR), and conventional RT-PCR. However, all the above-mentioned
detection methods challenge implementing specific, rapid, and simple diagnoses in laboratories
with insufficient resources. These challenges stem from excessive labor and time in testing, lack
of skilled personnel, adequate specificity and sensitivity, and costly equipment requirements [716].
Recently, RT-loop-mediated isothermal amplification (RT-LAMP) has been demonstrated
to have sensitivity equal to RT-PCR for the detection of swine enteric coronaviruses [17-20].
LAMP utilizes four to six primers and strand-displacing DNA polymerase. LAMP is carried out at a
constant temperature, without a need for temperature cycling [21]. Furthermore, LAMP is
compatible with multiple amplicon detection methods, including visual inspection with the naked
eye based on color changes or increased turbidity, gel electrophoresis, fluorescence, and
bioluminescence detection [22-26], and lateral flow strip immunochromatography, detecting
labeled amplicons using conjugated primer sets. Fluorescence and bioluminescence-based
detection methods enable real-time amplicon monitoring and quasi-quantification [27].
To implement diagnostic assays at the point of need, it is desirable to minimize manual
operations. This is best accomplished with microfluidic technology that enables the integration of
various unit operations. Here, we describe a 3D printed microfluidic device for real-time reversetranscription-LAMP that enables rapid, on-site molecular multiplexed detection and quasiquantification of PEDV, TGEV, and PDCoV (Fig. 2.1).
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Fig. 2.1: Workflow for the molecular diagnosis of PEDV, TGEV, and PDCoV in pigs. A sample is
collected with a rectal swab from a piglet and lysed to release and solubilize pathogenic viral
nucleic acids. The extracted nucleic acids are enzymatically amplified with RT-LAMP using the
microfluidic chip. The chip is incubated with a portable processor at a constant temperature. The
amplification products are monitored in real-time with an intercalating fluorescent dye and a lowcost CCD camera. Alternatively, end-point detection of amplicons using colorimetric dyes is also
feasible.
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2.2 Materials and Methods
2.2.1 3D-printed chip design and fabrication
Our 28 mm (L) x 28 mm (W) x 4 mm (H) microfluidic cartridge ‘chip’ (Fig. 2.2) features four
reaction chambers of 20 ± 1 μL volume each, connecting conduits, and passive capillary valves
to assist in flow control and sample distribution among the reaction chambers. The chip was
designed with SolidWorks 2018 software (DS SolidWorksTM) that produces CAD files in STL
format compatible with most 3D printers. The chip was then fabricated with a Low Force
Stereolithography (LFS) resin-based 3D printer (FormlabsTM, Form 3). The chip material is a clear
photopolymer resin (FormlabsTM, FLGPCL04) with a specific mass of 1.1 g cm-3 and thermal
conductivity of 0.110 W m-1 K-1. Portions of the 3D-printed chip are left uncapped to enable the
introduction of reagents. After printing, printing supports were removed, and the chips were
thoroughly washed with Form Wash (FormlabsTM) for 15 min, followed by a 15 min post-cure at
60 °C with Form Cure (FormlabsTM). To reduce the absorption of the enzymes and sample to the
reaction chambers’ surfaces that would adversely affect the efficiency of nucleic acid
amplification, we coated reactors’ inner surfaces with a 2% aqueous solution of Polyethylene
glycol (PEG) 3350 [28].
Next, primers specific to individual targets were dried in three of the (test) reaction
chambers, one primer set in each chamber. The fourth chamber was left primer-free to serve as a
negative (non-primer) control. To this end, we pipetted an aqueous solution of the designated
primer set specific to each target through the uncapped common conduit into each test reactor
(Fig. 2.3) and then dried the chip at room temperature for 2 h. Next, we placed the chip on a
cooled plate for molten PEG 930 loading. PEG 930 has a melting temperature of 36 ± 1 °C and
solidified in the PEG chamber (opening II, Fig. 2.2 and Fig. 2.3) soon after filling. Finally, the chip
was capped with a PCR tape (Bio-RadTM, MSB1001), leaving only two open ports, one for sample
introduction and the other to allow air to escape during sample loading (Fig. 2.3). All the
operations described above are to be carried out during the chip manufacturing process.
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Fig. 2.2: A schematic depiction of the design principles and fluid control with capillary circuits and
passive capillary valves. (A) 3D printed chip design. (B1) Driven by capillary force, the LAMP
solution (including templates) flows into reactors automatically. In the future, the LAMP mix will be
pre-stored in the reaction chambers in dry form, and only the sample will be introduced into the
chip. (B2) By placing an absorption pad at the sample inlet, capillary force helps dry any excess
aqueous solution in the common conduit and therefore cut off the connections between different
reactors. (B3) The chip is then paired with the processor and heated to its operating temperature
(63 °C). During the heating process, PEG 930 (with a melting temperature of around 37 °C) melts
and flows into the common conduits driven by capillary force to seal the chip.
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Fig. 2.3: Chip preparation: (A) after 3D printing, the chip is washed, post-cured, and coated with
PEG 3350. (B) Aqueous solutions of primer sets for PEDV, TGEV, and PDCoV are, respectively,
pipetted into chambers a, b, and c. Chamber d is left primer-free. (C) The melt of PEG 930 is
inserted into the PEG chamber and (D) allowed to solidify. (E) The chip is capped with a PCR
tape to seal the open conduits, leaving only the sample inlet, the air vent, and the PEG chambers
open. (F) The chip is then ready for sample introduction and LAMP incubation.

2.2.2 Auto-distribution and self-sealing
The microfluidic chip houses capillary circuits, passive capillary valves, and phase-change
materials to control the flow in the chip, thereby minimizing the need for actuators and manual
operations. Since the 3D-printed resin is hydrophilic with a static water contact angle of 47
degrees (Formlabs™ Inc.), any abrupt enlargement in a conduit's cross-section provides a
passive capillary valve that pins a liquid column's advancing meniscus [29] and halts the flow.
Our microfluidic chip has four different capillary valves of various dimensions that require different
pressures to bridge, enabling us to achieve our desired flow control objectives.
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Our sample solution includes the LAMP reaction mix and targets (RNA extracted from the
samples) but not primers. In the future, the LAMP reaction mix will be dry-stored in the reaction
chambers, and the sample solution will include only the extracted nucleic acids in a hydration
buffer. The sample is introduced at the sample inlet port (Fig. 2.2A). The liquid is driven into the
chip by capillary forces. As the sample imbibes into the chip, it fills the common conduit and the
LAMP reaction chambers and is halted with capillary valves I, II, and III (Fig. 2.2A). Then, the inlet
port is brought into contact with an absorption pad that drains liquid only from the common
conduit (Fig. 2.2B). Among the capillary valves, valve III has the smallest hydrodynamic diameter
of 0.8 mm and therefore the greatest pinning force, followed by valve II with an intermediate
hydrodynamic diameter of 1.5 mm (smallest pinning force), and valve I with a hydrodynamic
diameter of 1.3 mm. Therefore, during the draining process, valve III pins the menisci and retains
the LAMP reaction chambers filled with the sample while the liquid is removed from the
connecting conduit to prevent crosstalk during incubation and cleared from the vicinity of the inlet
port to facilitate subsequent sealing with PEG. The chip is now ready for incubation.
Next, we place the chip on the heater in our custom-made processor and heat it to the
LAMP incubation temperature of ~63 °C. The PEG melts at 36 ± 1 °C and flows by capillary force,
effectively isolating the LAMP reaction chambers from the ambient to minimize evaporation
during incubation. When the chip is cooled back to room temperature after incubation, the PEG
solidifies, sealing the LAMP chambers and preventing the release of amplicons to the ambient air.

2.2.3 Viruses, clinical samples, and LAMP primer design
PEDV (PC22A strain) propagated in Vero cells [9], TGEV (virulent Miller-M6 strain) propagated in
ST cells, and PDCoV strain OH-FD22 propagated in LLC-PK cells [11] were provided by the
Department of Veterinary Preventive Medicine, The Ohio State University, Wooster, OH, United
States, through a Material Transfer Agreement. RNA was extracted with an AM1836 5X MagMax
96 viral extraction kit (Life Technologies Corp.), following the manufacturer's instructions.
The number of copies of genomic RNAs of PEDV, TGEV, and PDCoV were quantified
[30] and diluted to 105 genomic copies per μL of each virus.
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Eleven rectal swabs were collected from piglets that previously tested positive for PEDV,
TGEV, or PDCoV with the gold standard virus-specific RT-PCR assays [7, 11, 12], and one
negative control rectal swab was collected from a non-infected gnotobiotic pig at Ohio State
University. Sample collection from pigs and extracted nucleic acid transportation were carried out
in compliance with the ethical guidelines of both Ohio State University and the University of
Pennsylvania, USA.

2.2.4 LAMP primer design
Sequences of various PEDV, TGEV, and PDCoV strain complete genomes were obtained from
the GeneBank and aligned to determine the conserved sequences with MEGA X software
(http://www.megasoftware.net/). A 277-nt sequence and 233-nt sequence in PEDV and PDCoV
nucleocapsid gene, respectively, and a 258-nt sequence in the ORF1ab gene of TGEV were
targeted as templates due to their homology among the analyzed strains and their divergence
from sequences of other organisms. LAMP primers (Fig. 2.4, Fig. 2.5, and Fig. 2.6) were
designed using the PrimerExplorer software (V5, Eiken Chemical Co. Ltd.). The designed primers
were checked for cross-hybridization with sequences of other viruses in the NCBI database
BLAST (http://www.ncbi.nlm.nih.gov) that infect the digestive tract of pigs, including swine acute
diarrhea syndrome-coronavirus (SADS-CoV), porcine respiratory coronavirus (PRCV), porcine
hemagglutinating encephalomyelitis virus (PHEV), porcine calicivirus, porcine parvovirus, and
porcine rotaviruses. There was no cross-reaction with any of these viruses. The LAMP primers
were synthesized (IDT Company, Coralville, IA), provided lyophilized, then suspended in
nuclease-free water (Invitrogen, Carlsbad, CA, USA) to a concentration of 100 μM.
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Fig. 2.4: Template regions and sequences of the LAMP primers for PEDV: (A) PEDV amplicon
gene sequence with the six primer locations: B3, F3, FIP, BIP, LF, and LB; arrows indicate the
direction of extension. (B) Sequences of the primers for the PEDV LAMP reaction.
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Fig. 2.5: Target regions and sequences of the LAMP primers for TGEV: (A) TGEV polymerase
gene sequence with the six primer locations: B3, F3, FIP, BIP, LF, and LB; arrows indicate the
direction of extension. (B) Sequences of the primers for the TGEV LAMP reaction.

28

Fig. 2.6: Target regions and sequences of the LAMP primers for PDCoV: (A) PDCoV
nucleoprotein gene sequence with the six primer locations: B3, F3, FIP, BIP, LF, and LB; arrows
indicate the direction of extension. (B) Sequences of the primers for the PDCoV LAMP reaction.

2.2.5 Benchtop RT-LAMP reaction conditions
The RT-LAMP reaction mix with a volume of 10 μL contained F3 and B3 primers (0.2 μM of
each), LoopF and LoopB primers (0.8 μM of each), FIP and BIP primers (1.6 μM of each), 6 μL of
Isothermal MasterMix (ISO-001, OptiGene, USA), 0.4 μL of 1 × EvaGreen® dye (Biotium Inc.,
Hayward, CA, USA), 0.2 μL of AMV reverse transcriptase (200 U μL-1 ) (Promega Corp.,
Madison, WI, USA), and 1 μL of the extracted RNA template, and nuclease-free water was added
to bring the total volume to 10 μL. Fluorescence emission of DNA amplicons was monitored with
the 7500 Fast Real-Time PCR system (Applied Biosystems, Carlsbad, CA, USA) at 65 °C for 30
minutes, then analysis of the melting curve from 50 °C to 95 °C with 1.0 °C increment per second
was performed. Positive and negative controls were included in each run. Positive controls were
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PEDV (PC22A strain), TGEV (virulent Miller-M6 strain), and PDCoV (OH-FD22 strain), while nontemplate rectal swabs from non-infected gnotobiotic pigs were used as negative controls.

2.2.6 Benchtop qRT-PCR reaction conditions
Each RT-PCR reaction volume comprised SsoFast EvaGreen® Supermix (Bio-Rad, USA) (5 μL),
primers F3 and B3 (10 μM), 0.2 μL of AMV reverse transcriptase (200 U μL-1), 1 μL of viral RNA,
and nuclease-free water to a 10 μL final volume. The cycling conditions were as follows:
incubation at 50 °C for 30 min (for reverse transcription), followed by incubation at 95 °C for 10
min (melting), and then 45 cycles at 95 °C for 10 s and at 60 °C for 30 s, followed by the analysis
of the melting curve in the temperature range from 50 °C to 95 °C with 1.0 °C increment per
second. Monitoring of fluorescence emission was carried out using the 7500 Fast Real-Time PCR
system (Applied Biosystems, Carlsbad, CA, USA). Positive and negative controls were involved
in each run.

2.2.7 On-chip detection and data analysis
During the test, the LAMP master mix is loaded into the 3D-printed microfluidic chip (Fig. 2.2) via
the inlet port, and each LAMP reactor is filled with 20 ± 1 μL of the master mix, which includes 12
μL of Isothermal MasterMix (ISO-001, OptiGene, USA), 0.8 μL 1 × EvaGreen® dye, and 0.8 μL
AMV reverse transcriptase (200 U μL-1), along with 1.4 μL RNA template of one of these viruses
and nuclease-free water to 20 μL.
The chip was then incubated in an inexpensive, homemade, portable heating system.
Our heating system is controlled with a Raspberry Pi (Raspberry Pi Foundation®, Pi 4 Model B)
and equipped with a polyimide Thermofoil™ heater (Minco®, HK6911) and a Type-K
thermocouple (Omega®, TT-K30-SLE). The microcontroller Raspberry Pi, the thin-film heater,
and the thermocouple are used to create a closed-loop proportional-integral-derivative (PID)
control system. During incubation, the chip is first heated up to 45 °C for 6 min to ensure auto-
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sealing prior to the LAMP amplification. Then, the heater’s temperature is increased to and
maintained at 65 °C for 30 minutes to incubate the LAMP reaction.
A portable USB fluorescence microscope (Dino-Lite®, AM4115T-GFBW) emitted
ultraviolet light to excite the EvaGreen® dye incorporated in the amplified DNA and to read the
real-time fluorescence emission (Fig. 2.1). The fluorescence microscope has seven built-in blue
LEDs (light-emitting diodes) for fluorescence excitation and a 510 nm emission filter suitable for
observing the EvaGreen® dye intercalated in the amplified DNA. The microscope is mounted on
top of the heating system to monitor all LAMP reactors simultaneously (Fig. 2.1).
Images of the chip during incubation were captured with the fluorescence microscope
once every minute. Regions selected by the user were analyzed with MATLAB (MathWorks™,
R2019a). The camera records red, green, and blue (RGB) intensity values for each pixel.
DinoCapture™ 2.0 software (AnMo Electronics Corp., Taiwan) bundled with the portable
fluorescence microscope then extracts the G (green) value from the RGB matrix of each pixel and
calculates the average G value among all pixels included in the region of interest. The average G
values of each LAMP reactor represent the relative fluorescence intensities. The averaged and
normalized G values are plotted as functions of time. The threshold time is defined as the time
that it takes the G value to reach half its peak intensity.

2.2.8 Limit of detection (LOD)
To determine the smallest number of copies of the PEDV, TGEV, and PDCoV genomes that
could be detected with our microfluidic device, benchtop real-time RT-LAMP, and qRT-PCR
assays, we prepared serial dilutions of the three virus RNAs suspended in nuclease-free water.

2.2.9 Clinical performance
We extracted nucleic acids from the eleven samples of diseased piglets and one negative control
rectal swab from a non-infected gnotobiotic pig. These samples were previously tested for PEDV,
TGEV, and PDCoV with RT-PCR assays [7, 11, 12]. Among the tested samples, five samples
showed positive results for PEDV, three tested positive for TGEV, and three were PDCoV31

positive. The negative control sample was negative for all three viruses. We retested all the
samples concurrently with our microfluidic RT-LAMP, benchtop RT-LAMP, and benchtop qRTPCR. Negative and positive controls were included in all these tests. Furthermore, we carried out
with our microfluidic device co-detection of samples containing nucleic acids from two different
viral species (e.g., PEDV + TGEV, PEDV + PDCoV, and TGEV + PDCoV) and all three virus
species (PEDV + TGEV + PDCoV).

2.3 Results
2.3.1 Analytical performance of benchtop RT-LAMP and RT-PCR
Fig. 2.7 (RT-LAMP) and Fig. 2.8 (RT-PCR) depict, respectively, the fluorescence emission
intensities (arbitrary units) as functions of time and number of cycles for different target
concentrations of gRNAs of PEDV, TGEV, and PDCoV and the signals' threshold times/cycles as
functions of each target concentration. The threshold time Tt is defined as the time until the
amplification curve achieves half its saturation value. The RT-LAMP and RT-PCR threshold times
are nearly linear functions of the log of the target concentration. RT-LAMP and RT-PCR have
similar limits of detection. The lowest detectable concentration (limit of detection) is 10 genome
copies per reaction for PEDV and PDCoV and 102 for TGEV. Analysis of the melting curve
revealed a single peak for both RT-LAMP and RT-PCR products (Fig. 2.9), revealing the absence
of non-specific products such as primer dimers. Negative controls and non-template controls did
not show any signal of positive amplification.
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Fig. 2.7: Benchtop real-time LAMP results with template concentration ranging from 0 to 105
copies per reaction. RT-LAMP amplification curves: (A) PEDV, (B) TGEV, and(C) PDCoV.
Standard curves with threshold times: (D) PEDV, (E) TGEV, and (F) PDCoV.
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Fig. 2.8: Real-time PCR amplification curves of PEDV (A), TGEV (B) and PDCoV (C). The
number of templates ranged from 0 to 105 genomic copies per reaction. The threshold times
(minutes) are depicted as functions of PEDV (D), TGEV (E), and PDCoV (F) concentration
(genome copies per reaction). N = 3.
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Fig. 2.9: Melting curve analysis of both RT-LAMP and RT-PCR products reveals a single peak.

2.3.2. Microfluidic chip analytical performances
Our microfluidic chip (Fig. 2.2) comprises four independent isothermal amplification reactors,
each with a dry-stored primer set specific to a designated target. The identity of the amplicon is
determined by the reaction chamber's location. All four reactors are within the camera’s field of
view, enabling us to concurrently monitor the fluorescence emission from all the LAMP reactors in
real time during LAMP incubation. When only one of the targets is present in the sample, the
corresponding LAMP reactor lights up, while the other reactors and the non-primer control (NPC)
remain dark (Fig. 2.10A - 2.10C). The analytical performance of the chip was evaluated in the
template concentration range from 0 to 102 genome copies per reaction and showed similar
results to the benchtop assays.
One of the advantages of our chip is its ability to concurrently test for the presence of
multiple targets in a sample, thus indicating comorbidities. To demonstrate this feature, we
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contrived samples spiked with one, two, and all three different viruses. In the presence of
comorbidities, either two test reactors or all three test reactors light up (Fig. 2.10D - 2.10G). Our
assay co-detected successfully PEDV + TGEV, PEDV + PDCoV, TGEV + PDCoV, and (PEDV +
TGEV + PDCoV).
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Fig. 2.10: Images of fluorescence emission at the end of the amplification process and reaction
chambers’ average fluorescence intensities as functions of time. Samples contain (A) PEDV only
– chamber no. 2, (B) PDCoV only – chamber 3, (C) TGEV only – chamber 4, (D) PEDV and
PDCoV – chambers 2 and 3, (E) PEDV and TGEV - chambers 2 and 4, (F) PDCoV and TGEV chambers 3 and 4, and (G) PEDV, PDCoV, and TGEV - chambers 2, 3, and 4.

Four parallel LAMP reactors enable our chip to perform multiplexed RT-LAMP to detect
all three targets concurrently with a non-primer control. To demonstrate this, we prepared mixed
samples with all combinations of PEDV, TGEV, and PDCoV for multiplexed test on chip. Our
assay managed to co-detect all combinations of the three viruses (Fig. 2.10 and Fig. 2.11).

2.3.3 Performance of the benchtop assays with clinical samples
The eleven samples from diseased piglets were tested for PEDV, TGEV, and PDCoV with our
benchtop RT-LAMP assays, our chips running RT-LAMP assays, and qRT-PCR (Fig. 2.11 and
Table 2.1). Based on earlier qPCR, five samples were positive for PEDV, three were positive for
TGEV, three were positive for PDCoV, and one was negative for all these pathogens. All the
samples were retested with qRT-PCR in our lab in proximity to our RT-LAMP tests. All benchtop
RT-LAMP and chip-based RT-LAMP assays had 100% selectivity and 100% sensitivity compared
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to our qRT-PCR and with the data provided by the laboratory from which the clinical samples
originated.

Fig. 2.11: Testing of the clinical samples from diseased piglets with the microfluidic-based LAMP,
benchtop RT-LAMP, and benchtop RT-PCR assays. (A) Microfluidic-based LAMP threshold time
as a function of qRT-PCR threshold cycle. (B) Benchtop RT-LAMP threshold time as a function of
benchtop qRT-PCR threshold time. (C) Chip RT-LAMP threshold time as a function of benchtop
RT-LAMP threshold time (● for PEDV samples; ■ for TGEV samples; ▲ for PDCoV).

Table 2.1: Threshold LAMP times (min) and threshold RT-PCR cycles of our microfluidic and
benchtop tests of our clinical samples.

Sample #

Our RT-PCR

PEDV 1
PEDV 2
PEDV 3
PEDV 4
PEDV 5
TGEV 1
TGEV 2
TGEV3
PDCoV 1
PDCoV 2
PDCoV3
Control

22.1
19.3
17.8
17.1
24.1
33.1
20.2
32.3
18.2
18.9
19.8
0.0

Our benchtop
RT-LAMP
7.3
6.4
5.4
5.0
8.3
10.3
7.2
10.0
10.1
10.5
11.1
0.0

Our chip-based
RT-LAMP
8.5
8.0
7.1
6.0
9.1
20.1
12.4
16.4
12.1
12.9
20.0
0.0

The benchtop RT-LAMP and the microfluidic RT-LAMP threshold times were shorter than
the qRT-PCR and trended similarly (Table 2.1). The threshold times of the benchtop RT-LAMP40

assay and microfluidic-based RT-LAMP correlated linearly (𝑅' = 0.7). The aggregated data of all
the threshold times in our chip (regardless of the target type) exhibited a weaker correlation (𝑅' =
0.4, Fig. 2.11A) with the qRT-PCR threshold cycle. A stronger correlation was, however, obtained
(𝑅' = 0.8 − 0.9) when each pathogen was analyzed separately (Fig. 2.12).

Fig. 2.12: Testing of clinical samples from diseased piglets with the microfluidic based-LAMP and
benchtop RT-PCR assays. Microfluidic-based LAMP-threshold time as a function of qRT-PCR
threshold cycle for PEDV (A), TGEV (B), and PDCoV (C) clinical samples.

2.4 Discussion and Conclusions
Swine enteric viruses such as PEDV, TGEV, and PDCoV are a major threat to the pig industry,
causing substantial economic losses [1, 4]. For example, losses due to PEDV are estimated at
$300,000 per year for a single 700 sow farrow-to-finishing herd [31]. To rapidly implement
suitable control measures to contain the infection, rapid molecular testing of suspected animals is
needed. Since PEDV, TGEV, and PDCoV are co-endemic and cause similar symptoms in
animals, it is highly desirable to co-test for all three pathogens. Currently, diagnosis for PEDV,
TGEV, and PDCoV in suspected pigs is carried out with laboratory-based RT-PCR assays. A
previous report [32] described multiplexed molecular detection of swine enteric coronaviruses
with RT-PCR combined with post-amplification detection with gel electrophoresis. In addition to
the complex, time-consuming operation, the necessity to open amplicon-rich tubes endangers
contamination of the workspace. Another report [33] described a multiplexed assay that uses
TaqMan-probes for specific detection of enteric coronavirus targets with real-time qRT-PCR.
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Such an assay requires an expensive thermal cycler with a multicolor reader, is limited in the
level of multiplexing, and has a 10-fold lower sensitivity than the singleplex assays, presumably
because probes emit less light than intercalating dyes and/or due to the competition for enzymes.
The various PCR-based assays require well-equipped facilities, possibly expensive
instruments, and trained personnel that typically are not available on farms and often are located
at a large distance away, which complicate testing and delay test results. To facilitate testing in
resource-poor settings such as rural areas and developing countries, we have developed new
benchtop singleplex RT-LAMP assays for detecting PEDV, TGEV, and PDCoV. RT-LAMP is
more suitable for use in resource-poor settings than RT-PCR. Since LAMP operates at a fixed
temperature, ranging from 60 °C to 65 °C, does not require precise incubation temperature, and
does not require temperature cycling, it can be incubated with simple instruments such as
ESEQuant TubeScanner (GmbH, Stockach, Germany), Genie II (Optigene, Horsham, UK), and a
water bath or even instrumentation and electricity-free with heating provided by an exothermic
chemical reaction of the type used in military rations and in ready-to-eat meals and temperature
regulation provided with a phase-change material (PCM) [34, 35] LAMP's constant temperature
operations also consume less power than the thermal cycling needed for PCR. LAMP products
can be detected with intercalating dyes and molecular beacons like PCR products. But, since
LAMP produces about an order of magnitude greater number of amplicons than PCR, LAMP
products and by-products can also be detected with colorimetric dyes that are visible to the naked
eye, eliminating the need for a reader. Furthermore, the fluorescence emission from LAMP can
be detected with the ubiquitous smartphone [34, 35]. Finally, LAMP assays are more tolerant of
contaminants than PCR assays [36], simplifying sample preparations. In summary, LAMP assays
are highly sensitive, specific, robust, can be carried out over a temperature range of 60-65 °C in
less than one hour, and are more suitable for use outside centralized laboratories than PCR [37,
38].
Our benchtop PEDV, TGEV, and PDCoV RT-LAMP assays perform on par with the gold
standard qRT-PCR assays with shorter processing times. Like the benchtop qRT-PCR, our RTLAMP assays are processed in closed tubes without a need to open the tube and transfer
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amplification products to a lateral flow strip – a process that risks contaminating the workspace
and rendering future negative tests false positives. Each of our RT-LAMP assays for PEDV and
PDCoV has a limit of detection of 10 gRNA molecules per reaction (Fig. 2.7). Our RT-LAMP
assay for TGEV has a limit of detection of 100 gRNA molecules per reaction (Fig. 2.7). These
detection limits are appropriate for early-stage infection detection [14, 39, 40]. Our assays'
threshold times correlate linearly with the log of template concentration, enabling the estimation of
the number of viruses in the sample.
To confirm our assays' clinical performance for virus detection, we tested eleven clinical
specimens from diseased pigs with our benchtop RT-LAMP assays. Our LAMP test results are in
excellent agreement with the gold standard qRT-PCR. We believe that our assays are ready for
field tests.
To enable convenient co-detection of co-endemic targets, we developed a microfluidic
system comprising a 3D-printed microfluidic chip and a simple processor. The 3D-printing
technology allows us rapid, low-cost prototyping. From earlier works on LAMP on chips that
typically process a single target at a time [28, 41], our chip hosts four independent reaction
chambers, enabling the co-testing for multiple co-endemic pathogens in a single sample at the
point of need. Three of our reaction (test) chambers are customized for testing each of the
pathogens PEDV, TGEV, and PDCoV by pre-storing the corresponding primer sets in the
reaction chambers. The fourth reaction chamber serves as a negative control. Our chip
architecture can readily accommodate a larger number of reaction chambers to enable the codetection of a larger number of targets if needed.
The loading and drying operations in our chip are driven by capillary forces and do not
require external instruments for flow control, in contrast to many other microfluidic devices that
require syringe pumps and centrifugal forces [42, 43]. We rely on capillary imbibition and capillary
valves to take an aliquot from the sample among the various reaction chambers and, after sample
filling, to sever the connections among the reaction chambers to eliminate any crosstalk and false
positives. Our chips self-seal with a temperature-actuated phase-change material (PCM). During
incubation, the melted PCM prevents evaporation in the reaction chambers and amplicons from
43

escaping and contaminating the workspace. After amplification, the PCM solidifies, tombing the
reaction mix. Given the limited scope of this study, we were not able to dry-store reagents inside
our chip. In the future, we will store all reagents inside the chip in dry form for long-term (over one
year) refrigeration-free shelf-life, and the sample will include only the extracted nucleic acids.
We demonstrated that our RT-LAMP chip has similar performance to our benchtop RTLAMP assays and that we can detect any of the targeted analytes in a single process as well as
comorbidities. The chip required a bit longer processing times than our benchtop RT-LAMP,
which we attribute to the lower performance of our heating system compared to the benchtop
equipment. We anticipate that with further improvements, our microfluidic system would enable
affordable molecular testing at the point of need by minimally trained personnel, providing timely
and actionable information to farmers. In conclusion, our field-deployable real-time RT-LAMP
assays and microfluidic chips have the potential to facilitate rapid, inexpensive, multiplexed
molecular detection and quasi-quantification of PEDV, TGEV, and PDCoV in basic veterinary
laboratories and pigs' farms.
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Chapter 3 Refrigeration-free Ready-to-use Microfluidic Chip for Single-stage
NAATs
3.1 Introduction
In this chapter, we describe an inexpensive, portable, refrigeration-free, ready-to-use 3D-printed
microfluidic device for real-time multiplexed molecular detection of the human immunodeficiency
virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV). In addition, an Android-based
smartphone application was developed to capture real-time images in the case of colorimetric
detection, carry out time-series image analysis of fluorescent images imported from a USB
camera, and interpret results.
Bloodborne viral infections are threats to global public health. Over 400 million people
worldwide are infected or co-infected with the three bloodborne viruses, Hepatitis B Virus (HBV),
Hepatitis C virus (HCV), and Human immunodeficiency virus (HIV) [1-5]. In the absence of early
diagnosis and treatment, blood virus infections have high morbidity and mortality, cause chronic
diseases, and endanger the blood supply. HBV causes liver hepatitis, cirrhosis, and
hepatocellular carcinoma, infecting nearly 1.5 million people and causing an estimated 0.8 million
deaths annually. Over 296 million people are living with HBV [6], of whom 90% are unaware of
their infection [7]. The hepatitis virus HCV causes both acute and chronic liver diseases, including
cancer [8], with roughly 1.5 million new infections and 0.3 million deaths annually. About 58
million people worldwide are currently infected with HCV [9]. HIV targets humans’ immune
systems, making infected people immunodeficient [10] and causing an estimated 0.7 million
deaths and 1.5 million new infections annually [11]. Only 60 % of HIV patients are continuously
taking antiviral drugs, and over 20% of infected individuals are unaware of their condition.
Approximately 2.3 million HIV-infected people are co-infected with HCV, and 2.6 million HIVinfected individuals are co-infected with HBV [12]. There is an urgent need for co-detection of
HIV, HBV, and HCV due to their common path of transmission, the impact of co-infections on
therapy, and the need to inform public health officials to enable them to enact informed policies
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and control measures. In view of the availability and affordability of treatments, simple, rapid, and
reliable point-of-care testing is essential, especially in resource-poor conditions.
The current standard HIV, HBV, and HCV diagnoses require a molecular test such as
PCR. A PCR-based molecular test requires stringent sample processing, skilled personnel, a cold
chain, and expensive laboratory-based equipment [13, 14], making it unfeasible and unaffordable
in resource-limited settings. Point-of-care testing that distinguishes between an active state of
infection and past infection can provide a direct linkage to care, keep patients engaged, increase
the number of tested patients, and provide means to monitor therapy’s efficacy [15].
Isothermal enzymatic nucleic acid amplification provides opportunities for simple and
sensitive molecular tests at the point of care. One such isothermal amplification method, loopmediated isothermal amplification (LAMP), uses up to six primers to obtain target-specific
amplification with strand displacement polymerase [16, 17]. LAMP has demonstrated high
sensitivity compared to other isothermal methods and has been successfully applied in various
tests. LAMP is an attractive alternative to the PCR test in point-of-care settings since LAMP does
not require thermal cycling and has greater tolerance to contaminants than PCR [18, 19].
Combined with simple platforms such as microfluidic chips and paper-based devices, LAMP
provides a promising means for point-of-care molecular tests [13, 20-24].
A simple, rapid, point-of-care diagnosis can play a key role in identifying infected
individuals during a visit to a doctor’s or dentist’s office, enabling proper follow-up and care. To
enable molecular diagnostics at the point of need such as patients’ home, it is desirable to
eliminate the need for cold-chain refrigeration.
Herein, we demonstrate an inexpensive, portable, refrigeration-free, and ready-to-use
microfluidic device for multiplexed molecular detection of HIV, HBV, and HCV. All the
components of the LAMP assay are dried on chip, enabling refrigeration-free storage under room
conditions. Our device with the dry-stored reagents utilizes the same capillary circuit that we
described in Chapter 2 for auto-distribution of sample solution and auto-sealing with the phasechange material. Our chip consists of four reaction chambers, one for each of the three targets
(HIV, HBV, and HCV) and one for negative control. Detection can be carried out at the end of the
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process colorimetrically without any instrumentation or in real-time with a fluorescent dye.
Incubation and detection were carried out with our portable, low-cost, custom processor that
comprises an electric resistance heater and a USB camera, which can be easily produced in
resource-poor settings.

3.2 Materials and Methods
3.2.1 Materials
KCl, MgSO4, (NH4)2SO4, betaine, tween 20, polyethylene glycol (PEG) 930 for auto-sealing, PEG
3350 for coating, and hydroxynaphthol blue (HNB) were purchased from Sigma-Aldrich (St. Louis,
MO, USA). Tris-HCl was purchased from Boston Bioproducts (Ashland, MA, USA). dNTPs were
purchased from Denville Scientific (South Plainfield, NJ, USA). 20X EvaGreen dye was
purchased from Biotium Inc. (Hayward, CA, USA). Warmstart Bst 2.0 polymerase was purchased
from New England Biolab (Ipswich, MA, USA). HBV plasma sample was purchased from
Seracare life science (Milford, MA, USA). HCV genotype 1 clinical research sample was
purchased from Discovery life science Inc. (Huntsville, AL, USA). HIV-1 control and isopropyl
alcohol (IPA) were purchased from Thermo Fisher Scientific (Waltham, MA, USA). Clear resin for
3D printing was purchased from Formlabs (Somerville, MA, USA).

3.2.2 Nucleic acid extraction
HIV (Thermo Fisher Scientific, Waltham, MA, USA), HBV (LGC Clinical Diagnostics, Milford, MA),
and HCV (Discovery Life Science, Huntsville, AL, USA) plasma samples were stored at -20 oC
prior to use. HBV dsDNA was extracted with Qiamp DNA extraction kit (Qiagen, Hilden,
Germany). HIV RNA and HCV RNA were extracted with Qiamp viral RNA extraction kits
(Qiagen). The concentrations of the purified nucleic acids were estimated with Qubit DNA assay
kit, NA HS assay kit, and fluorimeter (molecular probe life science, Waltham, MA, USA). Copy
numbers of each sample were calculated based on molecular masses (NCBI) and then mixed
with molecular water to form dilution series. Our estimated viral loads favorably agreed with the
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vendor’s (Thermofisher, Seracare, Discovery) data after converting international units (IU) to copy
numbers [25-27].

3.2.3 Chip fabrication
Our microfluidic chip was designed with SolidWorks 2020 (Dassault Systèmes, VélizyVillacoublay, France) and saved as an STL file. The file was processed with PreForm (Formlabs,
Somerville, MA, USA) - a print preparation software that generates print supports and controls
print layout and orientation. Then, devices were fabricated with Form 3 (Formlabs, Somerville,
MA, USA), a low-force stereolithography (LFS) resin-based desktop 3D printer. After 3D printing,
the chip was thoroughly IPA rinsed with Form Wash (Formlabs, Somerville, MA, USA) for 15 min
and post-cured with Form Cure (Formlabs, Somerville, MA, USA) at 60 °C for 15 min. Next, the
inner surfaces of microfluidic channels were coated with a 2% aqueous solution of PEG 3350 [23,
28].

3.2.4 Ready-to-use microfluidic chip
Our portable, 3D-printed, ready-to-use microfluidic device has a compact size (23 mm L x 27 mm
W x 10 mm H). The chip (Fig. 3.1a) consists of four independent LAMP reactors. Each of the first
three reactors pre-stores primer set specific to a designated target. The fourth reactor does not
store any primers and serves as a non-primer, negative control. All other LAMP assay
components were dry-stored on chip and re-activated with the sample elution buffer prior to use.
Both fluorometric and colorimetric detections were used, allowing, respectively, real-time
monitoring with a fluorescence camera and endpoint detection with either a smartphone or the
naked eye.
Each reactor (Fig. 3.1a) has a volume of 20 µL and a slanted roof to siphon any air
bubbles away from the observation window so that the air bubbles do not interfere with the signal
acquisition (Fig. 3.2). On one end, all four reactors connect to a common distribution conduit that
links to the inlet port of the chip. On their other ends, reactors connect to a side opening
dedicated to reaction mix insertion. The two sides of the reaction chambers are interconnected to
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prevent pressure differences (Fig. 3.3a). Our LAMP assay comprises two parts: A and B, each
stored separately [29]. Component A is stored in the reaction chambers next to their distal ends,
and component B is stored at the sample injection port. The reagents are introduced in liquid form
through the designated openings and dried in-situ under ambient conditions. Detailed chip
dimensions are shown in Fig. 3.1b. A 3D CAD drawing and a real photograph of the device after
LAMP incubation with the left three chambers showing positive and the rightmost one displaying
negative signals are shown in Fig. 3.1c - 3.1d.

(b)

(a)

(c)

(d)

Fig. 3.1: (a) Chip architecture and the tapered geometry of each reaction chamber to
accommodate bubble migration away from the imaging region. (b) Chip dimensions. (c) 3D
rendering and (d) photograph of the chip after LAMP amplification with left three reaction
chambers showing positive signals and the rightmost chamber as a negative control.
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Adopted slanted roofs

Fig. 3.2: Slanted roofs siphon air bubbles away from the observation windows with gravity. The
observation windows, enclosed by the dash lines, are the regions analyzed to calculate the
chamber-averaged fluorescence intensity.

The 3D-printed resin has a static water contact angle of 47 degrees (Formlabs,
Somerville, MA, USA) that enables the capillary imbibition of aqueous solutions into the
microfluidic chip. To control spontaneous liquid distribution driven by capillary forces, capillary
valves were integrated onto the chip. The capillary valve array prevents the reactors from
overflowing during auto-distribution and locks liquids within each reactor when the liquid in the
distribution conduit is drained with an absorption pad. The capillary valve cube (Fig. 3.1a)
comprises two capillary valves on two sides and prevents aqueous solutions from flowing into the
PEG channel and vice versa. To stop undesired fluid flow during chip preparation, all air vents are
blocked to build up downstream pressure inside the chip that counteracts the capillary action.
PEG 930 has a static contact angle smaller than 90 degrees with the 3D printing material,
which allows the capillary imbibition of the molten PEG 930 into the microfluidic chip to perform
sealing. With a melting temperature of around 37 °C, PEG 930 remains solid at room
temperature. The chip is auto-sealed after its temperature exceeds the PEG’s melting
temperature before the LAMP amplification starts.

3.2.5 Chip preparation
Since each reactor is dedicated to a designated target or negative control, it requires specialized
LAMP mixes with primer sets specific to the designated targets. The LAMP reaction mix was
stored in two parts. Both parts were applied to the chip in liquid form, and the solvent was allowed
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to evaporate. Part A in liquid form (10 µL) comprises target-specific primers (10.4 µM), Bst
polymerase (0.64 U), dNTPs (2.8 mM of each), MgSO4 (16 mM), and (NH4)2SO4 (20 mM). Part B
in liquid form (60 µL) comprises Tris-HCl (40 mM), KCl (20 mM), betaine (1.6 M), HNB (240 µM),
EvaGreen (5.0 µM). Part A is specific to each reaction chamber and defines the chamber’s
designation. In contrast, component B is common to all reaction chambers. Thus, component B is
dry stored at the sample injection port and, after hydration, shared by the entire reactor array.

Dry LAMP
mixture B

Seal the tape

Mixture B
1. Remove the tape
2. Dry LAMP mixture A
A1
A2
Cap the PEG chamber

PEG coating

Mixture
A3
A4

PEG 930

Fig. 3.3: Schematic illustration of the chip preparation process.

After chip fabrication, the PEG chamber and the side opening were sealed with PCR
tapes. LAMP mixture part B was then loaded into the reservoir and air-dried at 60 °C for 2 hr.
After component B formed a powder, we removed all the PCR tapes, inserted LAMP mixtures A
with specific primer sets into the corresponding reaction chambers via the side opening, and airdried the chip at room temperature for 4 hr. Next, the chip was placed on a cooled surface. Then,
molten PEG was poured into the PEG chambers and solidified immediately. Last, PCR tapes
were used to seal all openings leaving the sample injection port as the only port of the chip. The
chip preparation process is depicted in Fig. 3.3.
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3.2.6 Device operation
For each test, the extracted nucleic acids were eluted in nuclease-free water to a total volume of
120 µL and then inserted into the chip through its inlet port. The loading process can be done
either with a pipette or a dropper. Next, the PCR tape on top of the PEG chamber was peeled off
to trigger capillary action for the auto-distribution of the sample. The chip utilizes capillary circuits
for the uniform distribution of the sample among the reaction chambers. As the sample solution
enters each reactor, it hydrates and reconstitutes the LAMP reaction mix. After the four LAMP
reactors had been fully filled, we placed an absorption pad at the inlet port, draining liquid from
the distribution conduit while the liquids in the reaction chambers were retained in place with the
capillary valves located at the distal ends of the reaction chambers.

Fig. 3.4: Workflow of the ready-to-use chip for real-time amplification and detection. Nucleasefree water laden with target nucleic acids hydrates and reconstitutes the LAMP reaction mix,
enabling LAMP amplification at the proper incubation temperature with both real-time and
endpoint detection.
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Next, the chip was incubated with our custom processor that comprises a microcontroller
Raspberry Pi 4 Model B (Raspberry Pi Foundation, Cambridge, UK), a flexible thin-film heater
Thermofoil HK6911 (Minco, Minneapolis, MN, US), a thermocouple TT-K-30-SLE (Omega
Engineering, Norwalk, CT, US), and a portable fluorescence camera Dino-Light AM4113TGFBW
(AnMo Electronics, Taiwan, China). The system was programmed to first hold the microfluidic
chip at 50 °C for 5 min for auto-sealing and then at 63 °C for 1 hr for LAMP amplification.

3.2.7 Real-time fluorescence detection
Our processor provides a dark chamber during LAMP amplification that blocks all ambient light.
The fluorescence camera mounted over the chip was programmed to take one fluorescence
image every 1 min. The camera has built-in blue LEDs that excite the EvaGreen dye. In the
presence of dsDNA amplicons, the dye emits green fluorescence that can be detected through a
510 nm emission filter with the CCD camera. When LAMP amplification takes place, the emission
intensity of the fluorescent dye increases with time. Reactors that light up with fluorescence
indicate the presence of their designated targets.
The fluorescence images were saved as JPG files and then analyzed with MATLAB
R2021b (MathWorks, Natick, MA, US). The MATLAB program used the RGB values in the first
image as the baseline and subtracted these values from all subsequent images to create a new
set of image files. Next, the program automatically detected the locations of LAMP reactors.
Alternatively, the user can specify manually the regions within the reactors to be analyzed for
emission intensity. After reactor identification, the program calculates the average G (green)
value of the pixels within each reactor region for each image, normalizes these values with the
maximum G value observed among all four reactors throughout the entire incubation time, and
plots the normalized G values as functions of time (Fig. 3.11).
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3.2.8 Colorimetric detection
HNB is a colorimetric indicator that monitors the presence of Mg2+ ions under alkaline conditions
[30]. Since the LAMP amplification produces byproducts such as pyrophosphate ion that reacts
with Mg2+ ions, the Mg2+ ion concentration decreases during the LAMP reaction, resulting in the
color change of HNB from violet to blue [31]. Reactors that change color indicate the presence of
their designated targets. A cellphone (iPhone 12 Pro, Apple, Cupertino, CA, US) was used to
capture a photo of the microfluidic chip after 60-min LAMP amplification. The photo was then
analyzed with MATLAB R2021b (MathWorks, Natick, MA, US). Similar to the fluorescence image
analysis mentioned above, the locations of each reactor in the photo were identified first with
auto-detection or by manual selection. Then, the MATLAB program extracted R (red) and B (blue)
values from each imaging region, calculated the average B to R ratio for each reactor, normalized
these ratios with the value of the negative control, and plotted the ratio as bar charts (Fig. 3.8).

3.2.9 Smartphone application for image analysis
An Android-based smartphone application was developed with the platform MIT App Inventor
[32]. Four screens (Fig. 3.5) were created and dedicated, respectively, to program selection
(screen 1), camera settings (screen 2), region of interest identification (screen 3), and real-time
monitor and result interpretation (screen 4). Once the application is opened, the user is directed
to the home screen (screen 1) to select one from the three programs, i) real-time monitoring, ii)
colorimetric detection, and iii) fluorometric detection.
If the first program, real-time monitoring, is selected, the user is then transferred to
screen 2 (Fig. 3.5) to make any adjustment to the default camera settings, including camera index
(which specific camera to use – smartphones usually have multiple built-in cameras), flash mode,
focus mode, exposure compensation, etc. Once the camera settings are finalized, the application
transfers to screen 3 (Fig. 3.5), asking the user to confirm the reactor number and the regions of
interest for chamber-averaged intensity analysis. Next, the application switches to the last screen
(Fig. 3.5) and prompt the user to confirm the incubation time and the image acquisition frequency.
The default settings are 60 min of incubation and a photo capture frequency of one per minute.
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During incubation, the application acquires a photo at the specified frequency, displays the photo
on screen 4, calculates chamber-averaged signal intensities, and updates the real-time
amplification curve on screen 4. At the end of the incubation time, the application displays the
diagnostic results, pointing out which target pathogens are present.
If the second program, colorimetric detection, is selected, the user will go through a
similar process, confirming the camera settings (screen 2) and the regions of interest (screen 3).
On the final screen (screen 4), the application will take an endpoint photo of the chip, plot each
reactor’s chamber-averaged B to R ratio in a bar chart, and display the detection results.
If the third program, fluorometric detection, is selected, the program skips the camera
settings (screen 2) and goes through the same process for observation window confirmation
(screen 3). On the final screen (screen 4), the application is given access to the fluorescence
images uploaded to the smartphone. It then performs time-series image analysis, plots
amplification curves on screen 4, and displays the diagnostic results. All the tests of the
application were done with an Android smartphone (Mate 20 Pro, Huawei, Shenzhen, China).
More details of the application are provided in Supplementary Information.
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Screen 1

Screen 2

Screen 3

Screen 4

Fig. 3.5: User interface (UI) of the Android-based smartphone application developed with the MIT
App Inventor platform. Screen 1 is the home screen for program selection that appears when the
application is opened; Screen 2 allows camera setting adjustments; Screen 3 enables the user to
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confirm regions of interest; Screen 4 provides real-time monitoring, result display, and data
interpretation.

3.2.10 Estimation of potential cross-talk: primer migration
A 3D model with geometries complementary to our microfluidic chip was designed with
SolidWorks 2020 (Dassault Systèmes, Vélizy-Villacoublay, France) and saved as a STEP file.
The file was then imported into COMSOL Multiphysics (COMSOL, Stockholm, Sweden),
providing the geometry for the computational domain (Fig. 3.6). The simulation is based on a
time-dependent diffusive transport module with no-flux boundary conditions everywhere. The
diffusion coefficient for the primers was estimated based on the primer with the shortest length
(17 nt, Table 3.1) as 1.5 × 10-10 m2/s [33]. The reaction mix part A is assumed rehydrated when
all four reaction chambers are fully filled with the sample elution buffer and reconstituted in a 0.1mm thick layer coating the half of the LAMP reactors’ surface close to the side opening. Without
loss of generality, we report on the diffusion of primers from the second reactor from the left (Fig.
3.6). The primer concentration is normalized with its initial concentration. That is, the initial primer
concentration in the coated region is 1 and 0 elsewhere.

(a)

(b)

Fig. 3.6: Geometry of the microfluidic chip with four LAMP reaction chambers and the common
distribution for COMSOL simulation. The region highlighted is the 0.1-mm thick layer surrounding
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the half of the second LAMP chamber close to the side channel (representing reconstituted part A
of the reaction mix), where the normalized initial primer concertation was set to 1. The other
domains have a normalized initial primer concentration of 0.

3.3 Results
3.3.1 Simulation results
During the auto-distribution of the sample (~2 min), the various LAMP reactors are interconnected
via the distribution conduit. The COMSOL simulation was carried out to examine potential primer
migration among the LAMP reactors (cross-talk). As expected, our simulations indicate that an
insignificant quantity (< 0.01 %) of primers migrated out of their original reactor (Fig. 3.7a). The
primer concentration at the inlet of the adjacent reaction chamber (Fig. 3.7b) is negligible (less
than 0.01 % of the nominal primer concentration needed for LAMP amplification) within the 3-min
time interval when the passage among reactors is available for diffusion. The simulations suggest
that the cross-talk and false positives resulting from primers’ migrations (Fig. 3.7a - 3.7b) are
unlikely. The results of our numerical simulations were validated with a mesh-size convergence
(Fig. 3.7a) and a mass conservation (Fig. 3.7c) study. Our simulation is conservative, assuming
that i) the dried LAMP mixture A re-suspends immediately once all reaction chambers are filled
with the hydration solution, ii) the hydration solution remains quiescent and only diffusion
contributes to the migration, and iii) all six LAMP primers have the same diffusion coefficient of
1.5 × 10-10 m2/s obtained based on the shortest primer (Table 3.1). In practice, i) dried assay
resuspension requires time, up to minutes; ii) during the loading of the hydration solution, there is
advection in the direction from the common distribution conduit to reaction chambers’ distal ends
that would counteract diffusion; and iii) longer primers (Table 3.1) have even smaller diffusion
coefficients, which further lessen the possibility of cross-talk.
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(a)

(b)

(c)
0 min

1 min

2 min

3 min

Fig. 3.7: Simulations to estimate the primer migration from the second (from the left) reaction
chamber to the other reaction chambers. (a) Normalized primer concentration calculated with
three different mesh sizes at the inlet of the third (from the left) reaction chamber as a function of
time. (b) Representative images of primer concentration distributions within the reaction
chambers during the first few minutes after hydration prior to the draining of the distribution
conduit. (c) Total primer mass as a function of time.
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Table 3.1: Primer sequences of HIV, HBV, and HCV.

*HBV primer sequences were adapted from [34], HCV from [35], and HIV from [36].

3.3.2 Detection of HIV, HBV, and HCV
We prepared microfluidic chips for the multiplexed detection of HIV, HBV, and HCV in the left
three reactors, leaving the rightmost one primer-free as a negative control. Fig. 3.8 shows the
multiplexed LAMP results for six cases when 1) HBV only is present in the sample, 2) HCV only is
present in the sample, 3) HIV only is present in the sample, 4) HBV and HCV are present in the
sample, 5) all three targets are present in the sample, and 6) there are no targets present (no
template control).
The chips were incubated at 63 °C for 60 min in our custom processor with real-time
fluorometric (EvaGreen dye) and colorimetric (HNB dye) monitoring. We did not observe any
cross-talk, contamination, false positives, or false negatives.
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Fig. 3.8a displays fluorescence images taken at the end of each incubation. In each test,
only the reactors corresponding to the targets present in the sample lighted up, and the other
reactors remained dark. The normalized fluorescence emission intensities in each reaction
chamber are shown in the bar chart in Fig. 3.8a. Green fluorescence from dsDNA intercalating
dye increases as the number of LAMP amplicons increases. All the experiments single-plex – (1),
(2), (3), multiplex – (4), (5), and no-target control (6) show target-specific results. The assay
specificity was tested with samples laden with other pathogens such as HPV-16, HPV-18, and
ZIKV available in our lab. None produced any false positive (Fig. 3.9).

(a)

HIV HBV HCV NTC

HIV HBV HCV NTC

HIV HBV HCV NTC

HIV HBV HCV NTC

HIV HBV HCV NTC

HIV HBV HCV NTC

Intensity (a.u.)

1.0
0.6
0.4
0.2
0.0

(b)

Normalized B/R ratio

HIV
HBV
HCV
Negative

0.8

(1) HBV

(2) HCV

HIV HBV HCV NTC

HIV HBV HCV NTC

(3) HIV

HIV HBV HCV NTC

(4) HBV + HCV

(5) All

HIV HBV HCV NTC

HIV HBV HCV NTC

(6) None

HIV HBV HCV NTC

1.4
HIV
HBV
HCV
Negative

1.3
1.2
1.1
1.0
0.9

(1) HBV

(2) HCV

(3) HIV

(4) HBV + HCV

(5) All

(6) None

Fig. 3.8: Results of multiplexed LAMP amplification under various sample conditions with
concurrent use of a fluorescent intercalating dye (EvaGreen) and a colorimetric dye (HNB). (a)
Fluorescence images at the end of the 60-min incubation (top row), and the fluorescence intensity
of each reaction chamber (bottom row) normalized with the maximum fluorescence intensity
observed from all four chambers on the same chip. (b) Photographs of the colorimetric dye (top
row) and color quantification (bottom row). The sample contains (1) only HBV; (2) only HCV; (3)
only HIV; (4) both HBV and HCV; (5) HBV, HCV, and HIV; (6) non-template control.
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(4) HBV + HCV

(6) None

HPV-16

HPV-18

ZIKV

HIV HBV HCV NTC

HIV HBV HCV NTC

HIV HBV HCV NTC

HIV HBV HCV NTC

HIV HBV HCV NTC

Fig. 3.9: Specificity test of our microfluidic chip with samples containing HBV, HCV, Human
papillomavirus (HPV-16 and HPV-18), and zika virus (ZIKV).

The test results can be captured both in real-time (Fig. 3.8a) and at the end of the
incubation (Fig. 3.8b). Real-time measurement is carried out with a fluorescent dye whose
emission intensity is proportional to the number of amplicons. Fluorescence emission can also be
detected at the endpoint in the visible spectrum. It is also possible to detect that LAMP
amplification took place with a colorimetric dye such as HNB. The color of HNB dye changes from
violet to blue with successful LAMP amplification [31]. Here, we use both fluorescent intercalating
dye EvaGreen and colorimetric dye HNB. Both EvaGreen and HNB dye are pre-stored on chip in
the dry form together with the LAMP reagents. The detection results are read with the naked eye
and the smartphone application. To quantify the color signature, we extracted the R (red) and B
(blue) values from the pixels in the imaging region in each reactor, calculated the B/R ratio,
normalized this ratio with the corresponding value of the negative (non-template) control (Fig.
3.8b and Fig. 3.10c - 3.10d). We automated this whole with the custom-written smartphone
application, which can be used at the POCT without a need for any specialized instrumentation
(Fig. 3.10). The colorimetric results after 60-min amplification are displayed in Fig. 3.8b and are
consistent with the fluorometric detection (Fig. 3.8a).
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(a)

(b)

(c)

(d)

Fig. 3.10: Screenshots of the Android-based application for image analysis and result
interpretation. (a) The application performed time-series image analysis and plotted amplification
curves for each reactor. The plot is consistent with the result obtained with MATLAB. (b) The
same result as (a) with the region of interest of each reactor being specified. (c) The application
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performed image analysis, plotted each reactor’s chamber-averaged B to R ratio, and displayed
that the result for the second (from the left) reactor was positive. (d) The same result as (c) with
the region of interest of each reactor being specified.

3.3.3 Real-time analysis for HIV, HBV, HCV specific amplification
The amplification process was also monitored in real-time during incubation. Fig. 3.11a and Fig.
3.11b depict, respectively, two representative cases when only a single target (HBV) is present
and when all three targets (HIV, HBV, and HCV) are present. The figure also reports fluorescence
images at 0 min, 20 min, and 60 min of the LAMP amplification. Only reactors specific to the
present target(s) lighted up during incubation time.
Real-time curves enable us to estimate the target concentration in the sample based on
the time needed for the amplification curve to exceed threshold intensity. The threshold time was
defined as the time when the fluorescence emission reaches its half peak intensity. To
demonstrate the capability of quasi-quantitative analysis of our microfluidic chip, we performed
real-time LAMP with samples containing various concentrations of HBV and HCV. Samples were
serial diluted in nuclease-free water and transported to a ready-to-use chip for LAMP
amplification. Fig. 3.11c and Fig. 3.11d depict results with various concentrations of HBV DNA
and HCV RNA samples, respectively. The real-time curves in Fig. 3.11c and Fig. 3.11d are
sigmoid-shaped and shift to the right as the target concentration decreases. Similar to the
threshold cycle analysis of quantitative PCR, the threshold time of LAMP increases linearly as a
function of the logarithm of the target concentration in the sample (Fig. 3.11e - 3.11f). To
establish limits of detection, we need to carry out a much greater number of experiments than we
have done here. Our results indicate that we can detect down to 24 copies of HBV DNA and 76
copies of HCV RNA on chip. This detection sensitivity is comparable to that of the benchtop
laboratory equipment [4, 15, 37].
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0 min

20 min

0 min

60 min

(a)

(b)

(c)

(d)

(e)

(f)

20 min

60 min

Fig. 3.11: Real-time amplification curves for multiplexed detection of targets on chip. (a)
Fluorescent intensity emitted by an intercalating dye during the incubation of a sample containing
only HBV (2.4 × 105 copies), (b) Fluorescent intensity emitted by an intercalating dye during the
incubation of a sample containing HBV (2.4 × 105 copies), HIV (6.5 × 104 copies), and HCV (7680
copies). (c) Amplification curves for a dilution series of HBV DNA. (d) Amplification curves for a
dilution series of HCV RNA. (e) LAMP threshold times as functions of the number of HBV DNA
templates in the reaction volume. (f) LAMP threshold times as functions of the number of HCV
RNA templates in the reaction volume.
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3.3.4 Refrigeration-free storage of the microfluidic chip
To test the stability of our on-chip dried LAMP reagents, we prepared a few ready-to-use chips for
HBV detection, stored them in a dark environment at room temperature and humidity, and tested
the chips as a function of storage duration using the threshold time as the figure of merit. The
reagents were dried in ambient conditions without any stabilizers. The performance of our dried
reagents gradually decreased with storage time (Fig. 3.12), as reflected by the increase in the
threshold time of the LAMP tests. Our dry storage, refrigeration-free method enables us to store
chips for about 10 weeks in refrigeration-free conditions. This is likely insufficient for a commercial
product but good enough for laboratory testing of chip efficacy.

Fig. 3.12: Stability test of our on-chip dried LAMP reagents as a function of storage duration
under ambient conditions. Efficiency (y-axis) is defined as (Tt-Tt0)/Tt0, where Tt and Tt0 are,
respectively, the measured threshold time and the threshold time measured with freshly dried
reagents.

3.4 Discussion and Conclusions
We demonstrated a ready-to-use microfluidic device for multiplexed molecular detection of the
bloodborne pathogens: HIV, HBV, and HCV extracted from human plasma. Co-detection of these
pathogens is of significance since the routes of transmission of these three pathogens are similar,
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and many HIV-infected patients are also infected with HCV and HBV. Furthermore, in the case of
HCV, the standard of care mandates an antibody test followed up with a molecular test. A
procedure results in many patients being lost to care for the lack of follow-up. A rapid molecular
test at the point of need would facilitate the test and treat strategy.
Our device has several novel features and advantages. First, the flow control is based on
capillary circuits that enable spontaneous chip filling driven by capillary forces and eliminates the
need for more expensive moving members. Second, our thermally activated sealing with a phasechange material performs auto-sealing, which further simplifies the operational complexity and
increases user-friendliness. Third, both the chip and the custom processor are portable for POCT.
Fourth, fluorometric and colorimetric detections are carried out concurrently. The fluorometric
detection enables real-time monitoring of the LAMP amplification reaction and quasiquantification of the target concentration. Colorimetric detection enables readout with the naked
eye, eliminating the need for instrumentation. Fifth, we developed an Android-based smartphone
application that can process fluorescence images and endpoint photos to automate image
analysis and result interpretation, replacing the previously used laptop computer running
MATLAB. Sixth, all LAMP reagents were dry-stored on chip, making our chip ready-to-use and
refrigeration-free. With our current storage method, the dried LAMP reagents on chip last for at
least 10 weeks stored in a dark environment at room temperature and humidity. Seventh, the
four-channel design enables multiplexed molecular detection of HIV, HBV, and HCV, together
with a negative control. And we have shown that our chip has detection sensitivity comparable to
the state-of-art.
A low-cost, user-friendly, and refrigeration-free ready-to-use microfluidic device is the key
to molecular point-of-care testing for untrained individuals and resource-limited settings. Our
microfluidic device has demonstrated its feasibility to eliminate the needs of centralized laboratory
facilities and professional operators while maintaining a high detection sensitivity and specificity.
In future work, 1) the chip will be integrated with a superhydrophobic plasma separator
[38] to provide sample-to-answer capability; 2) the smartphone application will be augmented to
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provide thermal control for the incubation process in addition to the image acquisition and data
analysis.

73

References
[1]

UNAIDS. "AIDS statistics - 2021 fact sheet.".

[2]

C. Beyrer and A. Pozniak, "HIV drug resistance—an emerging threat to epidemic control," New
England Journal of Medicine, vol. 377, no. 17, pp. 1605-1607, 2017.

[3]

H. W. Chen, T. Belinskaya, Z. Zhang, and W. M. Ching, "Simple Detection of Hepatitis B Virus in
Using Loop-Mediated Isothermal Amplification Method," Mil Med, vol. 184, no. 7-8, pp. e275e280, Jul 1 2019, doi: 10.1093/milmed/usy421.

[4]

D. J. Shin, A. Y. Trick, Y. H. Hsieh, D. L. Thomas, and T. H. Wang, "Sample-to-Answer Droplet
Magnetofluidic Platform for Point-of-Care Hepatitis C Viral Load Quantitation," Sci Rep, vol. 8, no.
1, p. 9793, Jun 28 2018, doi: 10.1038/s41598-018-28124-3.

[5]

M. J. Alter, "Epidemiology of viral hepatitis and HIV co-infection," Journal of Hepatology, vol. 44,
pp. S6-S9, 2006/01/01/ 2006, doi: https://doi.org/10.1016/j.jhep.2005.11.004.

[6]

WHO. "Hepatitis B." https://www.who.int/news-room/fact-sheets/detail/hepatitis-b.

[7]

D. Razavi-Shearer et al., "Global prevalence, treatment, and prevention of hepatitis B virus
infection in 2016: a modelling study," The lancet Gastroenterology & hepatology, vol. 3, no. 6, pp.
383-403, 2018.

[8]

B. Maasoumy and H. Wedemeyer, "Natural history of acute and chronic hepatitis C," Best
practice & research Clinical gastroenterology, vol. 26, no. 4, pp. 401-412, 2012.

[9]

WHO. "Hepatitis C." https://www.who.int/news-room/fact-sheets/detail/hepatitis-c (accessed.

[10]

P. Piot, M. Bartos, P. D. Ghys, N. Walker, and B. Schwartländer, "The global impact of HIV/AIDS,"
Nature, vol. 410, no. 6831, pp. 968-973, 2001, doi: 10.1038/35073639.

[11]

WHO. "HIV/AIDS." https://www.who.int/news-room/fact-sheets/detail/hiv-aids (accessed.

[12]

L. R. Saud et al., "Hepatocellular carcinoma in patients coinfected with hepatitis B or C and HIV:
more aggressive tumor behavior?," European Journal of Gastroenterology & Hepatology, vol. 33,
no. 4, pp. 583-588, 2021.

74

[13]

B. S. Batule, Y. Seok, and M. G. Kim, "Paper-based nucleic acid testing system for simple and early
diagnosis of mosquito-borne RNA viruses from human serum," Biosens Bioelectron, vol. 151, p.
111998, Mar 1 2020, doi: 10.1016/j.bios.2019.111998.

[14]

M. Kubista et al., "The real-time polymerase chain reaction," Molecular Aspects of Medicine, vol.
27, no. 2, pp. 95-125, 2006/04/01/ 2006, doi: https://doi.org/10.1016/j.mam.2005.12.007.

[15]

Y. Seok, Q. Yin, H. Bai, and H. H. Bau, "Sensitive, Single-Pot, Two-Stage Assay for Hepatitis
Viruses," Analytical Chemistry, 2022.

[16]

N. Tomita, Y. Mori, H. Kanda, and T. Notomi, "Loop-mediated isothermal amplification (LAMP) of
gene sequences and simple visual detection of products," Nat Protoc, vol. 3, no. 5, pp. 877-82,
2008, doi: 10.1038/nprot.2008.57.

[17]

T. Notomi et al., "Loop-mediated isothermal amplification of DNA," Nucleic acids research, vol.
28, no. 12, pp. e63-e63, 2000.

[18]

L. Becherer, N. Borst, M. Bakheit, S. Frischmann, R. Zengerle, and F. von Stetten, "Loop-mediated
isothermal amplification (LAMP) – review and classification of methods for sequence-specific
detection," Analytical Methods, vol. 12, no. 6, pp. 717-746, 2020, doi: 10.1039/c9ay02246e.

[19]

N. A. Tanner, Y. Zhang, and T. C. Evans, Jr., "Visual detection of isothermal nucleic acid
amplification using pH-sensitive dyes," Biotechniques, vol. 58, no. 2, pp. 59-68, Feb 2015, doi:
10.2144/000114253.

[20]

R. R. G. Soares et al., "Sub-attomole detection of HIV-1 using padlock probes and rolling circle
amplification combined with microfluidic affinity chromatography," Biosens Bioelectron, vol. 166,
p. 112442, Oct 15 2020, doi: 10.1016/j.bios.2020.112442.

[21]

S. Hongjaisee et al., "Rapid visual detection of hepatitis C virus using a reverse transcription loopmediated isothermal amplification assay," Int J Infect Dis, vol. 102, pp. 440-445, Jan 2021, doi:
10.1016/j.ijid.2020.10.082.

75

[22]

H. Kong et al., "A RT-LAMP based hydrogen ion selective electrode sensing for effective detection
HIV-1 RNA with high-sensitivity," Sensors and Actuators B: Chemical, vol. 329, 2021, doi:
10.1016/j.snb.2020.129118.

[23]

M. El-Tholoth, H. Bai, M. G. Mauk, L. J. Saif, and H. H. Bau, "A Portable, 3-D Printed, Microfluidic
Device for Multiplexed, Real Time, Molecular Detection of Porcine Epidemic Diarrhea Virus,
Transmissible Gastroenteritis Virus, and Porcine Deltacoronavirus at the Point of Need," Lab
Chip, 10.1039/D0LC01229G 2021, doi: 10.1039/D0LC01229G.

[24]

S. C. Liao et al., "Smart cup: A minimally-instrumented, smartphone-based point-of-care
molecular diagnostic device," Sensor Actuat B-Chem, vol. 229, pp. 232-238, Jun 28 2016, doi:
10.1016/j.snb.2016.01.073.

[25]

J. Saldanha et al., "An international collaborative study to establish a World Health Organization
international standard for hepatitis B virus DNA nucleic acid amplification techniques," Vox
Sanguinis, vol. 80, no. 1, pp. 63-71, 2001, doi: https://doi.org/10.1046/j.14230410.2001.00003.x.

[26]

J. Saldanha et al., "World Health Organization collaborative study to establish a replacement
WHO international standard for hepatitis C virus RNA nucleic acid amplification technology
assays," Vox Sanguinis, vol. 88, no. 3, pp. 202-204, 2005, doi: https://doi.org/10.1111/j.14230410.2005.00606.x.

[27]

J. Song, C. Liu, M. G. Mauk, J. Peng, T. Schoenfeld, and H. H. Bau, "A Multifunctional Reactor with
Dry-Stored Reagents for Enzymatic Amplification of Nucleic Acids," Anal Chem, vol. 90, no. 2, pp.
1209-1216, Jan 16 2018, doi: 10.1021/acs.analchem.7b03834.

[28]

K. Kadimisetty et al., "Fully 3D printed integrated reactor array for point-of-care molecular
diagnostics," Biosensors and Bioelectronics, vol. 109, pp. 156-163, 2018/06/30/ 2018, doi:
https://doi.org/10.1016/j.bios.2018.03.009.

76

[29]

Y. Seok, B. S. Batule, and M.-G. Kim, "Lab-on-paper for all-in-one molecular diagnostics (LAMDA)
of zika, dengue, and chikungunya virus from human serum," Biosensors and Bioelectronics, vol.
165, p. 112400, 2020.

[30]

A. Ito and K. Ueno, "Successive chelatometric titration of calcium and magnesium using Hydroxy
Naphthol Blue (HNB) indicator," Bunseki kagaku, vol. 19, no. 3, pp. 393-397, 1970, doi:
10.2116/bunsekikagaku.19.393.

[31]

M. Goto, E. Honda, A. Ogura, A. Nomoto, and K. Hanaki, "Colorimetric detection of loopmediated isothermal amplification reaction by using hydroxy naphthol blue," Biotechniques, vol.
46, no. 3, pp. 167-72, Mar 2009, doi: 10.2144/000113072.

[32]

Shaileen and Jos\'e, "MIT App Inventor: Enabling Personal Mobile Computing," arXiv pre-print
server, 2013-10-24 2013, doi: None

arxiv:1310.2830.
[33]

I.-C. Yeh and G. Hummer, "Diffusion and Electrophoretic Mobility of Single-Stranded RNA from
Molecular Dynamics Simulations," Biophysical Journal, vol. 86, no. 2, pp. 681-689, 2004, doi:
10.1016/s0006-3495(04)74147-8.

[34]

Y. Seok, Q. Yin, H. Bai, and H. H. Bau, "Sensitive, Single-Pot, Two-Stage Assay for Hepatitis
Viruses," Analytical Chemistry, vol. 94, no. 3, pp. 1778-1786, 2022, doi:
10.1021/acs.analchem.1c04480.

[35]

L. V, "Application of Real Time Loop Mediated Isothermal Amplification Assay on Dried Blood
Spots in the Detection of HCV RNA among High Risk Patients," Journal of Emerging Diseases and
Virology, vol. 2, no. 1, 2016, doi: 10.16966/2473-1846.111.

[36]

J. Song et al., "Smartphone-Based Mobile Detection Platform for Molecular Diagnostics and
Spatiotemporal Disease Mapping," (in eng), Anal Chem, vol. 90, no. 7, pp. 4823-4831, Apr 3 2018,
doi: 10.1021/acs.analchem.8b00283.

77

[37]

N. B. Quoc, N. D. N. Phuong, and N. N. B. Chau, "Closed tube loop-mediated isothermal
amplification assay for rapid detection of hepatitis B virus in human blood," Heliyon, vol. 4, no. 3,
p. e00561, 2018.

[38]

C. Liu et al., "A high-efficiency superhydrophobic plasma separator," Lab Chip, vol. 16, no. 3, pp.
553-560, 2016, doi: 10.1039/c5lc01235j.

78

Chapter 4 Microfluidic Device with Capillary Circuits for Multiplexed, Two-stage
NAATs
4.1 Introduction
The microfluidic devices previously discussed in chapters 2 and 3 were developed for
multiplexed, single-stage NAATs. We have demonstrated with the LAMP assay that our devices
can be successfully used for the co-detection of three co-endemic pig viruses (PEDV, TGEV, and
TGEV) and three human bloodborne viruses (HIV, HBV, and HCV) that co-infect a significant
number of individuals worldwide. In earlier work, our group has developed a two-stage isothermal
enzymatic amplification that combines RPA and LAMP, dubbed Penn RAMP, to achieve a high
level of multiplexing. In some cases, Penn RAMP has also achieved higher sensitivity and better
tolerance to inhibitors than the standalone LAMP [1-4].
In benchtop settings (Fig. 4.1a), the first stage of Penn-RAMP is multiplexed RPA at
37 °C for 10-20 min in a single tube with RPA primer sets for all targets of interest; Next, the RPA
products are aliquoted into multiple LAMP tubes, each with a unique LAMP primer set dedicated
to a single target. The multiple LAMP reactors are then incubated with a thermal cycler at 63 °C
for 1 hr. The Penn RAMP in its benchtop format requires the user to open the amplicon-rich RPA
tube to aliquot the RPA products into various LAMP tubes [1], which risks contamination of the
workspace with amplicons and false-positive results in future tests.
To address this issue, our group developed a single-tube Penn RAMP, wherein the RPA
solution is loaded to the tube’s lid while the LAMP solution is loaded into the tube’s body (Fig.
4.1b). The thermal cycler’s block and lid temperatures are first set to the RPA incubation
temperature of 38-42 °C for 10-20 min. Next, the RPA solution in the lid is either spined down into
the tube with a centrifuge or mixed with the tube’s contents by turning the closed tube upside
down a few times. The tube is then incubated for 20-40 min with the block and lid temperatures
set to the LAMP incubation temperature of about 63 °C. During this entire process, the Penn
RAMP tube remains closed, eliminating the risk of contamination [3].
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A

B

Fig. 4.1: A schematic illustration of Penn RAMP in benchtop settings: (A) Penn RAMP comprises
a single tube for multiplexed RPA and multiple LAMP tubes, each dedicated to a single target [1];
(B) Penn RAMP in a single-tube format. The RPA is performed in the tube’s lid while the LAMP is
carried out in the tube’s body. The tube remains sealed at all times [3].

However, the Penn RAMP in a single-tube format has certain limitations: 1) Unless
probes with distinct emission spectra are used, the process is limited to detecting a single target;
2) The RPA and LAMP buffers are incompatible. The optimal RPA:LAMP volume ratio is around
1/15 [3]. When carried out in a single tube, typically, the RPA volume in the lid is 5 µL, which
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requires about 70-µL LAMP solution in the tube while a standalone LAMP can be carried out with
a volume of 10-20 µL. That is, the single-tube Penn RAMP consumes more reagents and is,
therefore, less cost-effective than standalone LAMP. In this chapter, we introduce a portable, lowcost, rapid, 3D-printed microfluidic device with capillary circuits for real-time molecular detection
of infectious laryngotracheitis virus (ILTV) in chickens with Penn RAMP.
ILTV is a DNA virus that belongs to the Gallid alphaherpesvirus 1 (GaHV-1) species of
the Alphaherpesvirinae subfamily within the Herpesviridae family [5-7] and causes a common
respiratory disease in chickens. The disease causes respiratory distress and leads to significant
production losses due to diminished egg production, poor feed conversion rates, high mortality
rates, and increased susceptibility to other respiratory tract pathogens [6, 8]. The rapid, specific,
simple molecular detection of ILTV at the point of need is crucial to enable chicken farms to take
timely action and contain the spread of infection.
Traditional diagnosis of the disease depends on clinical signs and necropsy ﬁndings.
Conﬁrmative laboratory diagnosis of ILT is performed by virus isolation, immunoﬂuorescence
techniques, neutralization assay, enzyme-linked immunosorbent assay (ELISA), as well as
conventional PCR and quantitative real-time PCR (qPCR) [6, 9-18]. However, the abovementioned diagnostic methods are unsuitable for simple, speciﬁc, and rapid ILTV detection
outside centralized laboratories, such as at rudimentary veterinary stations and particularly in
developing countries where expensive equipment and skilled staff are in short supply. The need
to send samples to centralized laboratories and await results may delay the implementation of
control measures with signiﬁcant adverse consequences.
Loop-mediated isothermal ampliﬁcation (LAMP) of nucleic acids is a simpler alternative to
PCR with a comparable sensitivity [19-23]. Penn RAMP is a two-stage isothermal molecular
detection that uses recombinase polymerase amplification (RPA) as the first-stage amplification,
followed by LAMP, the second stage [1, 3, 4]. Both LAMP and Penn RAMP use a stranddisplacing polymerase, obviating the need for a high-temperature ‘melting’ step and the
temperature cycling used in PCR. In contrast to PCR that uses a pair of primers, LAMP employs
four primers, in addition to two loop primers, which anneal to different regions of the nucleic acid
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template. The additional primers may improve speciﬁcity [24]. Moreover, compared to the
standalone LAMP assay, the two-stage nested Penn RAMP is more sensitive and tolerant to
inhibitors [1-4].
A molecular diagnostics test (NAAT, nucleic acid ampliﬁcation test) comprises two major
components: (A) Enzymatic ampliﬁcation and (B) Detection of the ampliﬁcation product, either
during ampliﬁcation (real-time) or post-ampliﬁcation (end-point detection). Multiple methods have
been reported for amplicon detection in LAMP assays, including gel electrophoresis [25],
ﬂuorescence [25], naked eye (turbidity or color change) [25], and bioluminescence [26-28]. In
bioluminescence and ﬂuorescence-based detection, LAMP amplicons are monitored in a realtime manner, enabling quantiﬁcation [29-31].
NAATs can be implemented in microﬂuidic formats, such as palm-sized plastic cartridges
with microscale ﬂuid circuits for sample processing and analysis [32, 33]. Such microﬂuidic chips
offer lower cost, automated and streamlined operation, portability, sample containment, and ease
of use, facilitating operation by laypeople. Multiple unit operations (e.g., lysis, nucleic extraction)
can be integrated into single-use (disposable) chips for nucleic acid ampliﬁcation tests [34, 35].
This chapter describes a LAMP assay and a Penn RAMP assay for ILTV detection and
the implementation of these assays in a microﬂuidic chip suitable for ﬁeld molecular detection and
quasi-quantiﬁcation of ILTV infection. Our microﬂuidic chip had four reaction chambers, one of
which acts as a negative control. The other three chambers can be used either to test three
different samples for the same pathogen or a single sample split across the three chambers to
detect co-morbidity with different pathogens.

4.2 Materials and Methods
4.2.1 Chemicals and materials
The clear resin FLGPCL04 for 3D printing was supplied from FormlabsTM (Somerville, MA, USA).
Polyethylene glycol (PEG) 3350 for chip surfaces’ coating was obtained from Sigma Aldrich, Inc.
(St. Louis, MO, USA). AM1836 5× MagMax 96 Viral Extraction kit was adopted from Life
Technologies™ (Ambion®, Austin, TX, USA). RPA and LAMP primers were ordered from
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Integrated DNA Technologies, Inc. (Coralville, IA, USA). Loop amp DNA ampliﬁcation Kit was
supplied from Eiken Chemicals Co. (Tokyo, Japan). Bst 2.0 WarmStartTM DNA polymerase was
purchased from New England Biolabs (Ipswich, MA, USA). EvaGreen® dye was supplied from
Biotium Inc. (Hayward, CA, USA). Nuclease-free water was acquired from Invitrogen (Carlsbad,
CA, USA). OptiGene ISO-001 isothermal mastermix was purchased from Pro-Lab Diagnostics,
Inc. (Round Rock, TX, USA). TwistAmp® Basic kit was purchased from TwistDxTM (Cambridge,
UK).

4.2.2. Virus and clinical samples
Previously isolated ILTV and 11 clinical samples from diseased chickens with respiratory distress
were supplied by the Department of Molecular Biology, School of Veterinary Medicine, University
of Pennsylvania (Philadelphia, PA, USA). The ILTV was propagated on chorioallantoic
membranes (CAM) of embryonated chicken eggs (ECEs), followed by identiﬁcation using
histopathology for the intranuclear inclusions detection and the virus detected molecularly by
conventional PCR [14]. The number of genomic DNA copies of ILTV was quantiﬁed as previously
reported [36]. The genomic concentration is 5 × 105 copies per µL.

4.2.3 DNA extraction
DNA/RNA extraction was carried out with AM1836 5× MagMax 96 Viral Extraction kit (Ambion®,
Austin, TX, USA) following the instructions from the manufacturer.

4.2.4 RPA and LAMP primers
Genomic sequences of various ILTV strains from the GeneBank were analyzed after alignment to
identify conserved sequences. A 296-nt sequence in the polymerase gene of ILTV was used as a
target due to its high similarity among the analyzed strains. The RPA and LAMP primers (Fig. 4.2)
were designed with the PrimerExplorer V5 software (Eiken Chemical Co. Ltd.). The designed
primers were screened using NCBI database BLAST (http://www.ncbi.nlm.nih.gov, accessed on 2
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February 2020) for cross-reaction with other chicken respiratory tract viruses, including Mareks
disease virus (MDV), Newcastle disease virus, and avian influenza viruses (H5N1, H9N2, and
H5N8). No cross-reaction was detected. The RPA and LAMP primers were diluted to a 100 µM
concentration using nuclease-free water.

Fig. 4.2: RPA and LAMP primers aligned along the ILTV amplicon. (A) ILTV amplified sequence
with the primers sites: F3, B3, BIP, FIP, LF, and LB. Arrows show the direction of extension. (B)
Primers sequence for ILTV RPA and LAMP assays. F3 and B3 primers were used for RPA, while
all six primers were used for LAMP.

4.2.5 Benchtop LAMP amplification
The LAMP assay was performed to detect the polymerase gene of ILTV using the loop amp DNA
ampliﬁcation Kit. The 10-µL reaction mixture consisted of LAMP primers (Fig. 4.2B), 5 µL of 2×
Reaction Mix, 0.4 µL of Bst 2.0 WarmStart DNA polymerase, 0.5 µL of 1× EvaGreen® dye
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(Biotium Inc., Hayward, CA, USA), 0.6 µL of viral DNA template, and nuclease-free water to the
total volume of 10 µL. Fluorescence signals from DNA ampliﬁcons were observed with the 7500
Fast Real-Time PCR system (Applied Biosystems, Carlsbad, CA, USA) for 30 min at 63 °C.
Template-free controls were included in each run to guarantee the absence of contamination.
Nucleic acid extracts of Escherichia Coli isolate, Newcastle disease virus (NDV), and infectious
bronchitis virus (IBV) were used as negative controls.

4.2.6 Microfluidic chip for Penn RAMP and LAMP
Our 3D-printed microfluidic chip (31 mm × 25 mm × 3 mm, Fig. 4.3a) consists of one RPA
chamber with a volume of 45 µL and four 20-µL LAMP reaction chambers. The chip was
designed with SolidWorks 2020 (DS SolidWorksTM, Waltham, MA, USA) and fabricated with a
low-force Stereolithography (LFS) 3D printer Form 3 (FormlabsTM, Somerville, MA, USA) using
the clear resin FLGPCL04 (FormlabsTM, Somerville, MA, USA). Fig. 4.3b - 4.3e depicts the chip
processing steps: The 3D-printed chips were post-processed with Form Wash (FormlabsTM,
Somerville, MA, USA) and Form Cure (FormlabsTM, Somerville, MA, USA) following the
manufacturer’s instructions; The inner surface of the LAMP and RPA reaction chambers were
then coated with polyethylene glycol (PEG) 3350 aqueous solution (2%) for 30 min to reduce the
absorbance of polymerase by the 3D-printed materials [37, 38]; Next, solutions with different
LAMP primers were loaded into the various LAMP reactors via the uncapped distribution channel,
and the chip was air-dried at room temperature for 2 hr; Last, the open distribution channel was
capped with a PCR tape.

4.2.7 Penn RAMP and LAMP amplification on chip
Since LAMP primers (Fig. 4.2B) were pre-stored in individual LAMP reactors during chip
preparation (Fig. 4.3c - 4.3d), the generic LAMP mixture (OptiGene ISO-001 isothermal
mastermix) sans primers could be loaded into the chip. The 20-µL generic LAMP mix comprised
12 µL of ISO-001 mastermix (OptiGene, Horsham, UK), 1 µL of EvaGreen® dye (Biotium Inc.,
Hayward, CA, USA), and nuclease-free water to the total volume of 20 µL. The 45-µL RPA
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reaction mix consisted of 1× rehydrated TwistAmp® Basic reaction mix (TwistDxTM, Cambridge,
UK), F3 and B3 primers (480 nM, Fig. 4.2B), 14 mM of MgAc, 2.7 µL of DNA template with
various concentrations, and nuclease-free water to 45 µL. When performing LAMP-only tests, the
pseudo-RPA reaction mix that does not include TwistAmp® Basic reaction mix was used. When
performing limit of detection tests with standalone LAMP, 1.2 µL of viral DNA template was added
to the 20-µL LAMP mixture, and the RPA chamber was left empty at all times.

86

(a)

Uncapped conduit
for primer pre-store

RPA reactor
RPA mix &
Mineral oil inlet

Capillary
valve cubes

Four independent
LAMP reactors
Mineral
oil inlet
LAMP mix &
Mineral oil inlet

(b)

(c)
Post-processing
and PEG coating

Primer pre-store

(e)

(d)

Capping the
distribution channel

Fig. 4.3: Schematic illustration of microfluidic chip design and chip preparation process.

Fig. 4.4 depicts the chip preparation: First, the generic LAMP mixture was loaded via the
LAMP inlet, followed by a draining step to remove the liquid from the common distribution channel
(Fig. 4.4A). In this process, the capillary valves retain the reaction mix in the LAMP reaction
chambers. Second, the RPA mixture was loaded via the RPA inlet followed by a draining process
to clear the head of the T-junction, taking advantage of a capillary vale to keep the RPA solution
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in place (Fig. 4.4B); Last, mineral oil was inserted to provide oil seal by isolating the reaction
solutions from the ambient (Fig. 4.4C). The chip was then ready for incubation. Next, the chip was
incubated with our custom processor (Fig. 2.1) that comprises an electric resistant heater
Thermofoil HK6911 (Minneapolis, MN, USA), a Type-K thermocouple Omega Engineering TTK30-SLE (Norwalk, CT, USA), a Raspberry Pi 4 Model B (Cambridge, UK), and a portable USB
camera DinoLite AM4113TGFBW (Taiwan, China). The Raspberry Pi works as a central
controller, reading the temperatures measured by the thermocouple, calculating the appropriate
power to be supplied to the heater based on a proportional-integral-derivative (PID) algorithm,
and adjusting the heater power with pulse-width modulation (PWM). The USB camera includes
seven built-in blue light-emitting diodes (LEDs) for excitation, an emission ﬁlter with a 510-nm
wavelength cut-off, a CCD camera detection, and a USB connection. This microscope is
appropriate for EvaGreen® dyes and can monitor all reactors simultaneously without the need for
scanning. The USB camera was mounted on the top of the custom processor and programmed to
take a fluorescence image every minute. During incubation, the chip was first heated up to 37 °C
for 10 min, followed by 63 °C for 30 min (Fig. 4.4D).

88

A
A1

A2

A3

B2

B3

B
B1

C
C2

C1

C3

D
RPA
37℃ for 10 min

LAMP
63℃ for 30 min

Observation window

Penn RAMP incubation
on a thin film heater

Fig. 4.4: A schematic depiction of device operation: (A) Loading the LAMP reaction mix for the
second-stage amplification (A2) followed by draining the common conduit that connects the
various LAMP chambers (A3). (B) Loading the RPA reaction mix for the first-stage amplification
(B2) followed by a draining excess RPA solution to make room for the sealing mineral oil (B3). (C)
Insertion of mineral oil for sealing. (D) Two-stage incubation with our custom processor.
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The fluorescence images in JPG format were then analyzed with MATLAB R2021b
(MathWorks, Natick, MA, US) and our Android-based smartphone application previously reported
in Chapter 3. Normalized fluorescence intensities of each LAMP reaction chamber were plotted
versus time. We defined the threshold time as the time when the fluorescence emission reaches
its half peak intensity.
The speciﬁcity of our microﬂuidic chip was assessed by testing various pathogens
available in our laboratory such as IBV (8 × 105 gRNA copies per µL), NDV (103 gRNA copies per
µL), E. coli (1010 PFU per µL), transmissible gastroenteritis virus (TGEV, 103 gRNA copies per
µL), porcine epidemic diarrhea virus (PEDV, 103 gRNA copies per µL), and porcine
deltacoronavirus (PDCoV, 103 gRNA copies per µL). Each microorganism was tested three times
and presented a negative result, while controls tested with appropriate primers and, otherwise,
identical conditions were positive.

4.2.8 Penn RAMP simulation
The Penn RAMP on-chip implementation was examined with a COMSOL simulation to better
understand the migration of primers, reaction buffers, and nucleic acid amplicons among the
various reaction chambers. A 3D model of our microfluidic chip (Fig. 4.3a) was constructed with
SolidWorks 2020 (DS SolidWorksTM, Waltham, MA, USA) and imported into the COMSOL
Multiphysics (COMSOL, Stockholm, Sweden) software, providing the geometry for the numerical
simulations (Fig. 4.5). COMSOL’s Chemistry, Transport of Diluted Species, and Laminar Flow
modules were selected to simulate, respectively, on-chip RPA amplification, on-chip LAMP
amplification, and evaporation-induced fluid flow. The Transport of Diluted Species module was
also used to study the convective and diffusive transport of all species of interest.
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Fig. 4.5: Geometry complementary to the microfluidic chip with one RPA and four LAMP reaction
chambers for COMSOL simulation.

The simulation of the RPA amplification involves 15 species (Table 4.1) and 12 chemical
reactions as reported in Moody [39] with a few modifications/corrections (Table 4.2). The
simulation of LAMP was implemented with an empirical mathematical model previously reported
in Liu [40]. The empirical LAMP model is a logistic equation that requires the minimum and
maximum concentrations of the target nucleic acids and a single reaction rate constant (obtained
from Liu’s paper [40]) as inputs. To examine the interference between RPA and LAMP buffers,
we use CLAMP buffer and C RPA buffer to denote, respectively, the dimensionless LAMP buffer and the
RPA buffer concentrations normalized with their initial values. That is, the initial CLAMP buffer is 1 in
the LAMP reaction chambers and 0 in the RPA chamber, while the initial C RPA buffer is 0 in the
LAMP reaction chambers and 1 in the RPA chamber. Due to the evaporation during the LAMP
amplification and the resulting advection, the CLAMP buffer in the LAMP chambers gets
concentrated. We hypothesize that the LAMP reaction would only occur where the local CLAMP
buffer

is smaller than 1.2. Since the LAMP amplification works reasonably well when blended with

the RPA buffer in the ratio of 1:9 [3], we assume that the LAMP reaction takes place only when
the local CLAMP buffer is larger than 0.9 and the local C RPA buffer is smaller than 0.1. Next, according
to our heating settings, we limited the RPA reaction to the first 10 min and the LAMP amplification
between 15 and 60 min. We assumed that the heating and the RPA reaction start immediately
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after filling. The time window between 10 and 15 min is for temperature ramp-up from the RPA to
the LAMP working temperature.

Table 4.1: Species of interest involved in simulating the RPA amplification as reported in Moody
[39].
Species
D
F
G
P
R
dNTP
PPi
FD
FG
FGR’
FGR
FGnR’
FnR
FnRD
PFD

Description
DNA template
Primers
Single-stranded DNA binding protein
Polymerase
Recombinase complex
Deoxyribonucleotide triphosphate
Inorganic pyrophosphate
The complex formed between F and D
The complex formed between F and G
The unstable complex formed among F, G, and R
The stable complex formed among F, G, and R
The complex formed among F, G, and R
The complex formed between F and R
The complex formed among F, R, and D
The complex formed among P, F, and D

Table 4.2: Chemical reactions involved in the RPA amplification as reported in Moody [39] with
few corrections. m and n are, respectively, the number of binding sites for G and R on a primer.
Chemical Equations
𝒎 × 𝑮 + 𝑭 ⇌ 𝑭𝑮
𝑹 + 𝑭𝑮 ⇌ 𝑭𝑮𝑹′
𝑭𝑮𝑹- ⟶ 𝑭𝑮𝑹
𝑭𝑮𝑹 + (𝒏 − 𝟏) × 𝑹 ⇌ 𝑭𝑮𝒏𝑹′
𝑭𝑮𝒏𝑹- ⟶ 𝑭𝒏𝑹 + (𝒎 − 𝟏) × 𝑮
𝑭𝒏𝑹 + 𝑫 ⇌ 𝑭𝒏𝑹𝑫
𝑭𝒏𝑹𝑫 + 𝒏 × 𝑨𝑻𝑷 ⟶ 𝑭𝑫 + 𝒏 × 𝑹 + 𝒏 × 𝑨𝑴𝑷 + 𝒏 × 𝑷𝑷𝒊
𝑭𝒏𝑹𝑫 + 𝒏 × 𝑨𝑻𝑷 ⟶ 𝑭𝑫 + 𝒏 × 𝑹 + 𝒏 × 𝑨𝑫𝑷 + 𝑯𝟑 𝑷𝑶𝟒
𝑭𝑫 + 𝑷 ⇌ 𝑷𝑭𝑫
𝑷𝑭𝑫 + 𝟐 × 𝑩 × 𝒅𝑵𝑻𝑷 ⟶ 𝑷 + 𝟐 × 𝑩 × 𝑷𝑷𝒊 + 𝟐 × 𝑫
𝑭𝑫 + 𝒏𝒑 × 𝑷𝑷𝒊 ⟶ 𝑫 + 𝒏𝒑 × 𝒅𝑵𝑻𝑷
𝑫 + 𝑩 × 𝑷𝑷𝒊 ⟶ 𝑩 × 𝒅𝑵𝑻𝑷 + 𝑭𝑫

Corrected
Corrected
Corrected
Corrected

The Laminar Flow module comprised an open boundary at the inlet of the RPA chamber,
four outlets with the same velocity of 5 x 10-7 m/s at the inlets of LAMP reactors, and a no-flux
boundary condition for all other surfaces (Fig. 4.5). In reality, the inlet of the RPA chamber is
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sealed with mineral oil. When evaporation takes place at the water-air interface between the
LAMP reaction chambers and the common distribution conduit, the mineral oil penetrates the
RPA chamber. By measuring the distance that the water-oil interface has advanced during
incubation and assuming a constant evaporation speed, the constant velocity at the four outlets
was determined experimentally.
The Transport of Diluted Species module was coupled with the Laminar Flow module and
used the flow field calculated by the Laminar Flow module to simulate advective and diffusive
species transport. The Transport of Diluted Species module had zero-flux boundary conditions
everywhere. The diffusion coefficients of all species of interest except the DNA amplicons and
primers were set to 1001 m2/s. The DNA template’s and primer oligos’ diffusion coefficients were
set to 100&2 m2/s [40].
The mesh was set to Free Tetrahedral, followed by a Corner Refinement and a Boundary
Layers mesh with default settings. The default, time-dependent segregated solver was selected.
To validate the simulation results, we performed (i) a mass conservation study where
𝐶3+45 was integrated over the entire domain, normalized with its initial value, and plotted versus
time, and (ii) a mesh convergence study.

4.2.9 Analytical sensitivity
To determine the minimum number of ILTV nucleic acids that our LAMP assay could detect with
our microﬂuidic device, we carried out ten-fold serial dilutions of ILTV (2.5 × 104 genome copies
per reaction) suspended in nuclease-free water. Each dilution was tested three times.

4.2.10 Detection of nucleic acids from clinical samples
Extraction of the nucleic acids from 11 nasal swabs collected from diseased chickens was carried
out with AM1836 5× MagMax 96 Viral Extraction kit. The extracted nucleic acids were tested for
ILTV by PCR as previously described [14]. The extracted nucleic acids were analyzed for ILTV
with our microﬂuidic chip. Positive and negative controls were included in all tests.
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4.3 Results
4.3.1 ILTV LAMP performs on par with qPCR
We carried out ampliﬁcation of a dilution series of ILTV with LAMP. As the genome concentration
decreases, qPCR’s threshold cycle (Ct) increases nearly linearly as a function of the logarithm of
the template’s concentration [41]. Like the PCR threshold cycle, the LAMP threshold time (Tt) is a
linear function of the log of template concentration (Fig. 4.6). The smallest detectable ILTV
genome copies are 250 copies per reaction volume for both the qPCR [41] and the LAMP assays
(Fig. 4.6).

Fig. 4.6: Quantitative detection of ILTV with real-time LAMP: The LAMP threshold time (minutes)
as a function of the log of ILTV concentration (genomic DNA copies per reaction). N = 3.

4.3.2 Auto-distribution driven by capillary forces
The auto-distribution of the reaction mix driven by capillary forces was imaged with yellow and
blue food coloring (McCormick). Water with yellow food dye was used to represent the LAMP
solution, while water with blue food dye was used to mimic the RPA reaction mix. The on-chip
capillary circuits successfully i) aliquoted the LAMP solution into the four LAMP reaction
chambers (Fig. 4.7a - 4.7c), ii) allowed an absorption pad to drain liquid from the distribution
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channel while maintaining the solution in the LAMP reaction chambers intact (Fig. 4.7d - 4.7f), iii)
filled RPA chamber (Fig. 4.7g - 4.7i), and iv) enabled the removal of excess RPA solution without
draining the RPA reaction mix (Fig. 4.7j - 4.7l). Our chip with capillary circuits accommodates the
loading of two different solutions into adjacent chambers while maintaining a clear interface
between the two miscible solutions (Fig. 4.7l).
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Fig. 4.7: Demonstration of the operation of the capillary circuit for auto-liquid distribution. Water
dyed with blue and yellow food coloring is used, respectively, as a surrogate for the LAMP and
RPA reaction buffers.
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4.3.3 COMSOL simulation results
In contrast with the Penn RAMP’s benchtop settings, wherein RPA and LAMP solutions are
separate during the first-stage incubation and have an RPA:LAMP volume ratio of 1/15 in the
second stage, the RPA and LAMP reaction chambers on chip stay interconnected at all times.
We performed a COMSOL simulation to assess potential interference between RPA and LAMP
buffers and evaluate the potential risk of cross-contamination caused by the migration of LAMP
primers and LAMP amplicons from one LAMP reaction chamber to another LAMP reaction
chamber.
The interference between RPA and LAMP was simulated by assigning a representative
concentration to each buffer. CLAMP buffer and C RPA buffer represent, respectively, the LAMP buffer
concentration and the RPA buffer concentration normalized with their initial concentrations. The
presence of LAMP buffer in the RPA chamber CLAMP buffer was computed at the end of the RPA
reaction (time = 600 s) along the central line of the RPA chamber (Fig. 4.8a) and across the
entire domain. At the end of the RPA reaction, the central line of the RPA chamber has CLAMP buffer
smaller than 0.1 (Fig. 4.8b), which is deemed small enough not to affect the RPA reaction
significantly.
C RPA buffer was computed at the end of the LAMP reaction (time = 3600 s), along the
central line of the first (from left) LAMP chamber (Fig. 4.8a) and across the entire domain. The
simulation results (Fig. 4.8c) show that by the end of the LAMP reaction, the entire region of
interest within the LAMP chamber has C RPA buffer smaller than 0.2, and in the majority of the
reaction chamber, C RPA buffer is smaller than 0.1. Based on prior reports [3], LAMP performs
reasonably well when blended with RPA buffer in the ratio of 1:9. Thus, it is hypothesized that the
current chip design does not significantly decrease the efficiency of the LAMP reaction.
The DNA amplicon concentrations at three selected locations in the RPA chamber (Fig.
4.8d) were computed during the RPA reaction between 0 s and 600 s. Since the diffusion was
enabled for all the species involved in the RPA reaction (Table 4.1), the RPA reaction is under
suboptimal conditions. The closer to the LAMP reaction chambers, the lower the RPA
amplification efficiency (Fig. 4.8d). The initial amount of the DNA template in the RPA chamber is
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3.3 × 10-15 mol (initial concentration: 1 × 10-7 mol/m3). At the time (t = 900 s) when the LAMP
amplification starts, a total of 7.2 × 10-14 mol RPA amplicons have migrated into the four LAMP
chambers, 1.8 × 10-14 mol each, which is 5 times the initial amount of DNA template added into
the RPA chamber. For the primer-free, negative control where the LAMP amplification is disabled,
at the end of the LAMP incubation (t = 3600 s), there are in total 2.2 × 10-13 mol RPA amplicons
that have been transported to the LAMP reactors, 5.5 × 10-14 mol each LAMP chamber which is
16 times the initial amount of DNA template added into the RPA chamber. The RPA amplicon
distributions were shown in Fig. 4.8e. The simulation results proved our microfluidic chip design is
effective in aliquoting the first-stage amplicons into second-stage reaction chambers and
consistent with the observation that the two-stage amplification is about 10-fold more sensitive
than the standalone LAMP.
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Fig. 4.8: Simulation results of RPA-LAMP interference at the end of the RPA and the LAMP
reactions. (A) The computational domain and the locations of the RPA chamber’s central line ````
𝐴𝐵,
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```` of the first (from the left) LAMP chamber, and the locations of points E, F, and
the central line 𝐶𝐷
G in the RPA chamber. (b) The normalized LAMP buffer concentration at the end of the RPA
```` and
reaction (time = 600 s) as a function of position along the RPA chamber’s central line 𝐴𝐵
across the entire domain (color-coded). (c) The concentration of the normalized RPA buffer
concentration at the end of the LAMP reaction (time = 3600 s) as a function of position along the
```` and across the entire domain (color-coded). (d) RPA amplicon
LAMP chamber’s central line 𝐶𝐷
concentrations at three selected locations during RPA reaction as functions of time during the
RPA reaction. The initial DNA template concentration in the RPA chamber is 1 × 10-7 mol/m3. (e)
RPA amplicon concentrations at the beginning (t = 900 s) and the end (t = 3600 s) of the LAMP
reaction as a function along the central line of the primer-free LAMP reaction chamber (negative
control).

The risk of cross-contamination was estimated based on primer migration and LAMP
amplicon migration among reaction chambers. CLAMP primer denotes the LAMP primer
concentration normalized with its initial value. Since typically primers are provided in large
excess, we do not account for primer depletion during the LAMP amplification. We examined the
case when the leftmost LAMP reaction chamber is the primer-free, negative control and the other
reactors are positive controls. That is, the initial CLAMP primer is 0 in the leftmost LAMP chamber and
1 in the other LAMP chambers. This is the worst-case scenario because there is a net flow from
right to left in the RPA chamber and there are net flows from the RPA chamber into the LAMP
reactors due to the evaporation at the air-liquid interface between the liquid-free distribution
channel and the LAMP reactors. As mentioned in the methods section, this evaporation rate was
measured experimentally and specified in the numerical model as flow boundary conditions
facilitating advection. At the end of the Penn RAMP process (time = 3600 s), a negligible number
of primers (less than 0.01 % of the nominal primer concentration needed to support LAMP
amplification) has migrated out from their home chambers to the primer-free control chamber
(Fig. 4.9a), suggesting that false positives due to primer migration are unlikely. At the end of the
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Penn RAMP process (time = 3600 s), the observation window of the primer-free control has local
DNA amplicon concentrations smaller than 4% of the value in the test LAMP reaction chamber
(Fig. 4.9b), indicating that the template migration is unlikely to produce any signal (false positive).
Since the worst-case scenario was simulated, our estimates of primer and amplicon migration
among reaction chambers are conservative.

Observation
window

(a)
Primer-free
chamber
Normal
LAMP chamber
Normal
LAMP chamber

Normal
LAMP chamber

Observation
window

(b)
Chamber 1
(Primer-free)

Chamber 2
(Normal)

Fig. 4.9: Simulation results of primer migration among reaction chambers in Penn RAMP. The
leftmost LAMP chamber is primer-free control. (a) Computed normalized LAMP primer’s
concentration along the central line of the primer-free LAMP chamber at the endpoint of Penn
RAMP (time = 3600 s). (b) Computed distribution of DNA amplicons across the entire domain at
the endpoint of Penn RAMP (time = 3600 s) and the concentration of DNA amplicons along the
central lines of the primer-free chamber and a positive LAMP chamber at various times (time =
1800 s, 2100 s, 2400 s, 3600 s).
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Furthermore, to verify our simulation setup, we monitored the mass conservation during
the entire simulation (Fig. 4.10a) and performed a mesh convergence study (Fig. 4.10b). The
mass conservation study was carried out by integrating the LAMP buffer concentration CLAMP Buffer
over the entire domain and normalizing it with its initial value. During the simulation, the LAMP
buffer mass increased by 0.9 % (Fig. 4.10a), which we consider reasonable. To verify that the
numerical simulation converges, we examined the effect of mesh refinement on the RPA
amplicon distribution at the end of the RPA reaction (time = 600 s). The DNA amplicon
concentrations were computed along the central line of the leftmost LAMP reactor. The results
(Fig. 4.10b) suggest that our results are reasonably mesh-size independent.

(a)

(b)

Fig. 4.10: Examination of the viability of the numerical simulations. (a) Mass conservation during
the simulation – CLAMP Buffer was integrated over the entire domain and normalized with its initial
value. (b) Mesh convergence result – The DNA amplicon concentrations along the central line of
the leftmost LAMP reaction chamber at the endpoint of the RPA reaction (time = 600 s) were
computed with different mesh sizes.

4.3.4 ILTV detection on chip with real-time LAMP
The microﬂuidic chip used in our study has four independent LAMP reactors (Fig. 4.3a). Nucleic
acid ampliﬁcation was monitored in real-time by observing the ﬂuorescence emission of the
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EvaGreen® dye included in the LAMP reaction mix. When a template was present in the sample,
the corresponding LAMP chamber emitted fluorescence, while the chambers specialized for the
absent templates and the negative control chamber remained dark during the entire incubation. In
our experiments, three reaction chambers (1, 2, and 3) store primers for ILTV, while the fourth
chamber is a no primer control (Fig. 4.11). We carried out serial dilution LAMP on chip with the
number of templates ranging from 25 to 25,000 copies per reactor. Fluorescence emission was
detected in real-time with our homemade processor. Our microfluidic chip successfully detected
250 copies of ILTV (Fig. 4.11A), providing comparable sensitivity to the benchtop settings (Fig.
4.6). The threshold time correlated linearly with the log of the template concentration (Fig. 4.11B).
Fig. 4.11C is the fluorescence image of the chip after LAMP amplification, wherein only the
reaction chambers (1, 2, and 3) that contained primer sets for ILTV emitted fluorescence while
the non-primer control remained dark, consistent with our numerical simulations’ predictions (Fig.
4.9b). To examine specificity, we tested other samples available in our laboratory: IBV, NDV, E.
coli, TGEV, PEDV, and PDCoV (Fig. 4.12). None caused any fluorescent emission. That is, there
were no false positives.

A)

B)

C)

1

2

3

4

Fig. 4.11: (A) Real-time ampliﬁcation curves of microﬂuidic chip-based ILTV LAMP assays with
25000, 2500, 250, and 25 genome copies per reaction. (B) Fluorescence image of LAMP reactors
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(1, 2, 3: reaction chambers pre-stored with ILTV primers; 4: primer-free control). (C) The
microﬂuidic chip-based LAMP threshold time Tt (minutes) as a function of the log of ILTV
concentration.

A)

-ve
control

ILTV

IBV

PEDV

B)

Fig. 4.12: (A) End-point fluorescence image of the LAMP assay specificity test on chip with 1)
negative control, 2) ILTV positive sample, 3) IBV positive sample, and 4) PEDV positive sample.
(B) Reactor-averaged ﬂuorescence intensities as functions of time, showing successful
amplification of the ILTV sample only.

4.3.5. LAMP assay performance with clinical samples
Eleven ﬁeld samples collected from diseased chicken ﬂocks were used to screen for ILTV with
our benchtop real-time LMAP and our microﬂuidic device. Both our benchtop and on-chip ILTV
LAMP detection had 100% sensitivity and 100% selectivity in comparison with the gold-standard
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qPCR (Table 4.3, [41]). The on-chip (Fig. 4.13A) and benchtop (Fig. 4.13B) LAMP threshold
times correlated linearly with the qPCR threshold cycle and were shorter than the PCR
processing time. The threshold times of benchtop and microﬂuidic-based LAMP assays
correlated linearly (Fig. 4.13C). The benchtop LAMP threshold times were shorter than the
microﬂuidic LAMP due to the higher temperature ramping rate of the former.

Table 4.3: Results of clinical performance of our developed assays for ILTV detection. The qPCR
incubation time equals 𝑡! + 𝑡" × 𝐶6 , where 𝑡! is the initial incubation time of 2 min at 95 °C and 𝑡"
is the cycle time of 35 s (95 °C for 30 s and 60 °C for 5 s). The PCR assay performance was
published in Mohamed [41].

Sample No.

ILTV Detection Threshold Time

1
2
3
4
5
6
7
8
9
10
11

qPCR (Ct)
21
26
22
25
22
21
28
25

LAMP (Min)
14
17
15
16
15
14
19
16

LAMP on chip (Min)
18
21
19
20
21
18
22
21

Negative control

-

-

-
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Fig. 4.13: Clinical performance of our benchtop LAMP, benchtop PCR, and on-chip LAMP when
testing samples from diseased chickens. (A) Microﬂuidic chip-threshold time as a function of PCR
threshold cycle. (B) Benchtop LAMP threshold time as a function of PCR threshold cycle. (C)
Microﬂuidic device threshold time as a function of benchtop LAMP threshold time. The PCR
assay data was published in Mohamed [41].

4.3.6 On-chip Penn RAMP
We carried out a control experiment to verify that 1) both stages of amplification are functioning
on chip and 2) the sensitivity of Penn RAMP outperforms standalone LAMP. 102 copies of ILTV
were added to the RPA reaction mix and shared by all four LAMP reaction chambers, resulting in
an effective sample concentration of 25 copies per LAMP reaction. We used pseudo-RPA
solution without TwistAmp® Basic reaction mix as the control, while our experimental group used
standard RPA solutions. As before, ILTV primer sets were pre-stored in three out of four reaction
chambers, leaving the last one a primer-free negative control. In the absence of RPA enzymes,
the LAMP chambers did not emit any fluorescence, while in the presence of RPA enzymes,
fluorescence emission was detected, enabling the construction of amplification curves (Fig. 4.14),
suggesting that both RPA and LAMP functioned on chip. All the three reactors in our test group
detected 25 copies of ILTV, indicating that the sensitivity of our Penn RAMP is about 10-fold
better than the sensitivity of our standalone LAMP (Fig. 4.11). The Android-based smartphone
application that was introduced in chapter 3 was also used to carry out the image analysis of our
Penn-RAMP chip. Instead of analyzing the fluorescence images with the MATLAB software on a
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laptop computer, the images were imported into the smartphone and processed with the Androidbased application discussed in Chapter 3.2.9. The smartphone's results (Fig. 4.14c) are
consistent with the results generated with the laptop computer (Fig. 4.14a).
The multiplexing capability of Penn RAMP was demonstrated with on-chip Penn RAMP
detection of contrived samples comprising chicken virus ILTV and E. coli. In each test, only the
chambers with primers specific to the targets present in the sample lighted up, and the other
reactors remained dark (Fig. 4.15). No false positives were observed.

a)

b)

45 min

0 min

LAMP
Control

ILTV 1

ILTV 2

ILTV 3

Control

ILTV 1

ILTV 2

ILTV 3

ILTV 1

ILTV 2

ILTV 3

Control

ILTV 1

ILTV 2

ILTV 3

Control

RAMP

c)

Fig. 4.14: Comparison of Penn RAMP chip and standalone LAMP chip. Penn RAMP successfully
detected 25 copies of ILTV in all three reaction chambers while the standalone LAMP failed to
detect 25 copies per reaction volume: (a) Real-time chamber-averaged fluorescence intensities
as functions of time, (b) Initial and end-point images of LAMP reaction chambers, and (c)
Screenshots of the Android-based smartphone application used for analyzing the time-series
images of Penn RAMP with and without the regions of interest specified.
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b)

a)

Control

ILTV 1

E. coli

ILTV 2

Control

ILTV 1

E. coli

ILTV 2

Fig. 4.15: Chamber-averaged fluorescence intensities as functions of time and end-point
fluorescence images of Penn RAMP and standalone LAMP microfluidic chips customized to
detect both ILTV and E. Coli. Sample (a) contains both ILTV (1020 copies per RPA reaction
volume) and E. coli (1000 copies per RPA reaction volume), and sample (b) contains only ILTV
(1020 copies per RPA reaction volume). In each case, the leftmost reaction chamber is primerfree, serving as a negative control, and the other three chambers pre-store, respectively, ILTV, E.
coli, and ILTV primer sets.

4.4 Discussion and Conclusions
ILT presents a major risk to the chicken industry [8]. Rapid, point-of-need molecular detection
methods are critical to promptly instigate control measures to contain the spread of the disease in
the flock. This requires samples from suspected animals to be tested either in or in proximity to
poultry farms. Simple molecular tests that can be carried out by minimally trained personnel and
without sophisticated equipment would enable poultry farms operators to guard their farms
against devastating diseases.
To address this need, we have developed a new LAMP and Penn RAMP assay for ILTV
nucleic acids. LAMP and Penn RAMP assays have proven to be sensitive, speciﬁc, and robust [1,
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3, 32, 42] and share a few important advantages over the PCR used in centralized laboratories.
LAMP and Penn RAMP operate at ﬁxed temperatures and do not require temperature cycling,
which significantly diminishes equipment complexity, power consumption, and total setup cost.
Furthermore, the isothermal incubation for LAMP and Penn RAMP can be carried out even
electricity-free with a heat-generating, exothermic reaction and a phase-change material to
regulate the temperature [43]. Moreover, LAMP and Penn RAMP assays tolerate inhibitors effects
better than PCR [1, 44], allowing less stringent sample preparations. Finally, LAMP and Penn
RAMP produce more amplicons than PCR, facilitating instrument-free detection with a variety of
colorimetric dyes.
Our ILTV LAMP and Penn RAMP assay can be carried out in benchtop settings in a tube
with standard laboratory equipment or in a microﬂuidic device. Here, we describe a 3D-printed
microﬂuidic chip with one RPA chamber and four LAMP reaction chambers for Penn RAMP or
LAMP-only assays on chip. The chip utilizes capillary circuits, encoding the desired liquid
distribution within the geometry design. The aliquoting of RPA amplicons relies on convectiondiffusion effects, facilitating uniform distribution of first-stage amplicons into multiple second-stage
reactors without the need for actuators. The chips described herein comprise 4 LAMP reaction
chambers. The concept can be expanded, however, to include much greater number of LAMP
reaction chambers to facilitate high-level multiplexing. Our microﬂuidic chip mates with an
inexpensive, portable processor that provides temperature control and fluorescence detection.
Our ILTV LAMP assay, either on the benchtop or in microﬂuidic format, performs on par
with the gold-standard qPCR assay, and the sensitivity of our Penn RAMP assay outperforms our
LAMP-only assay by about 10-fold. Both our assays combine ampliﬁcation and detection in a
closed system without the need to transfer amplicons to a lateral ﬂow strip or electrophoresis gel,
avoiding exposing amplicon-rich solutions to the ambient and risking possible contamination of
the workplace, which may render false positives in subsequent tests. The threshold times of both
our benchtop and chip-based LAMP correlate linearly with the logarithm of initial ILTV DNA
concentration. Thus, we can use the threshold time to estimate the viral/pathogen load. The
somewhat longer threshold times in our microﬂuidic-based LAMP compared to benchtop assays
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result from the one-sided heating of our chip. In the benchtop instrument, the reaction chamber
(tube) is inserted into a heated metal block. In contrast, our microﬂuidic chip is heated only at its
bottom and is exposed to the ambient at its top. The heating efficiency can be, however,
improved with two-sided heating with a slight increase in complexity and cost, which were
deemed non-essential.
Both our benchtop and microﬂuidic ILTV LAMP assays achieved the sensitivity of 250
genomic copies per reaction, while the ILTV Penn RAMP demonstrated a higher sensitivity of 25
genomic copies per LAMP reaction chamber. During the early stage of infection, a chicken
typically has ILTV in respiratory tissues and secretions exceeding 103 genome copies/µL [16, 17].
Therefore, our assays’ detection limits are more than sufﬁcient for virus detection during the
seroconversion window.
To evaluate the clinical utility of our ILTV LAMP assay and its implementation in the
microﬂuidic format, we tested 11 clinical samples from diseased chickens, demonstrating
concordance with the gold-standard PCR and no interference from the inhibitors in clinical
veterinary samples.
In future work, it may be desirable to differentiate vaccines from pathogen strains. This
would require the design of more speciﬁc primers to inform appropriate control measures.
Additionally, integrating a simple and rapid technique for pathogen nucleic acids extraction and
concentration from crude samples with the chip would enable higher sensitivity [43].
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Chapter 5 Conclusions and Outlook
5.1 Conclusions
In this thesis, three portable, low-cost, 3D-printed, microfluidic devices with capillary circuits were
developed for rapid, simple, sensitive, specific, multiplexed point-of-need molecular detection of
human, animal, and plant pathogens. These devices utilize capillary-driven flow to aliquot
samples to multiple reaction chambers, capillary valves for flow control, and phase-change
materials for device sealing. To examine the efficacy of our technology, we developed and tested
assays for a few specific conditions. We developed a chip with multiple loop-mediated isothermal
amplification (LAMP) reaction chambers operating with liquid reagents to co-detect three coendemic pig viruses: PEDV, TGEV, and PDCoV (Chapter 2); a chip with multiple LAMP reactors
and dry-stored reagents to co-detect the three human bloodborne viruses: HIV, HBV, and HCV
(Chapter 3), and a chip that accommodates our custom-designed two-stage amplification dubbed
RAMP to detect chicken respiratory viruses such as ILTV (Chapter 4). Although these various
pathogens were used to assist chip development, their rapid detection is critical in many
circumstances. PEDV, TGEV, and PDCoV are re-emerging coronaviruses (CoVs) that cause
significant economic loss to pig farms and pork processors. HIV, HBV, and HCV have infected
and co-infected more than 400 million people worldwide and are causing millions of deaths and
new infections annually. ILTV presents a major risk to the chicken industry, causing a viral
disease in chickens’ respiratory systems and imposing considerable economic burdens on the
chicken industry.
Capillary circuits are the infrastructure that enables automated flow distribution and
control in all the microfluidic devices discussed in this thesis. I developed a capillary valvecontrolled draining process, allowing precise removal of liquids from one of the interconnecting
conduits and, more importantly, restoring function to capillary valves. In contrast to conventional
capillary valves that are single-use, the capability of re-activating previously used capillary valves
enables my capillary circuits to achieve more sophisticated control functions. For example, the
capillary circuit in Chapter 4 demonstrates its capability of loading two miscible aqueous solutions
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into adjacent microfluidic chambers while maintaining a sharp interface between the two solutions
and allowing the auto-distribution of two reaction mixes for on-chip Penn RAMP. Besides
aqueous solutions, the capillary circuits introduced in Chapters 2 and 3 also proved compatible
with a phase-change material (PEG 930) for capillary-induced automatic sealing.
Isothermal nucleic acid amplification tests (LAMP and Penn RAMP) were adopted in all
three microfluidic devices and performed on par with the gold standard PCR assays in benchtop
settings that require thermal cycling. The selection of isothermal molecular detection reduced the
design complexity of our microfluidic devices and heating/incubation system. Our assays are also
compatible with colorimetric dyes such as HNB dye that changes color from violet to blue when
successful amplification takes place, enabling instrument-free operation and result reading. To
avoid the need for a cold chain, a fully dried LAMP assay was implemented in Chapter 3,
demonstrating the capability of reaction mix storage at room temperature and humidity, obviating
the need for storage at -20 °C. The dried LAMP reaction mix can last for at least 10 weeks of onchip storage and perhaps much longer with further optimization.
A COMSOL-based numerical simulation was developed to model RPA and LAMP
amplification, fluid flow, and the migration of species of interest on chip, ultimately guiding the
microfluidic chip design. The simulations in Chapter 3 verified that the temporary liquid
connection among LAMP reaction chambers does not result in a significant amount of targetspecific primers migrating out of their designated chamber and into adjacent chambers. The
simulation in Chapter 4 modeled the on-chip Penn-RAMP reaction, evaporation-induced fluid
flow, and convective-diffusive species transport, estimating the potential risk of cross-talk and
potential interference between RPA and LAMP. Our numerical simulations verified that the
migration of primers and amplicons is unlikely to cause cross-contamination and the compositions
of RPA and LAMP reaction mixes are not significantly changed by the end of on-chip RPA and
LAMP amplification.
An Android-based smartphone application was developed to replace computers to
perform image analysis. In Chapter 3, the smartphone was used to take an endpoint chip photo
and interpret colorimetric detection results. In Chapters 3 and 4, the Android application was,
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respectively, used to analyze time-series fluorescence images for quasi-quantification of HIV,
HBV, and HCV viral loads and ILTV viral load.

5.2 Outlook
On-chip detection is rapid, sensitive, and specific, enabling the prompt implementation of
appropriate control measures to contain the spread of infections. Multiplexed detection is needed
to detect co-endemic pathogens that induce similar symptoms but require diverse infection
management strategies and to identify co-morbidities that may alter the course of a disease and
challenge standard drug therapies. Detection at the point of need is desired to provide health care
providers with critical information to enable personalized medicine and public health officials with
critical information to make rational policy decisions.
Our work in this thesis focused on the development and testing of the back end of the
diagnostic system. We addressed the aliquoting of purified nucleic acids into specific reaction
chambers, refrigeration-free reagent storage, reaction incubation, and amplicon detection. The
front-end sample-specific processing, such as serum separation from whole blood and nucleic
acid extraction and purification, is left to future work. It is desirable to integrate all unit operations
on a single substrate to provide sample-to-answer capability. To achieve this, our devices can be
combined with standalone portable devices for sample processing, such as Penn’s
superhydrophobic plasma separator [1]. It would, however, be more desirable to integrate all the
necessary unit operations into a seamless workflow, enabling automated processing with minimal
user intervention.
The capillary circuits developed herein eliminate the reliance on external control
instruments such as syringe pumps and pipettes. The draining and the pumping modules form
the two basic modules for my capillary circuits. More complex fluid distribution could be potentially
achieved by making more extensive use of these two simple operations.
The thermal control used in my devices requires electrical power either from the grid or
from a battery, a central controller to form a closed feedback loop and adjust power output based
on real-time measurements, a thermocouple, and an electric resistance heater, to maintain the
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desired incubation temperature. The need for such an incubator may increase the cost of our
device. In the future, incubation could be performed, electricity-free, with heat from an exothermic
reaction such as the one used in meals ready to eat and with phase-change material for
temperature control [2, 3].
There is a large parameter space for drying conditions and on-chip storage conditions
that has not been systematically explored. For example, one could optimize the temperature,
humidity, pressure, and time that are used to dry the reaction mix and the use of preservatives. A
better understanding of the on-chip reaction mix drying and storage will further increase the shelf
time of the microfluidic chip - something that would be essential in a commercial product.
3D printing was used to fabricate all the devices discussed in this thesis. I used a
commercially available 3D printer that was designed for home use. Using a professional 3D
printer with higher printing resolution will allow fabricating microfluidic channels with smaller
dimensions and therefore stronger capillary valves to provide more reliable flow control and
achieve more sophisticated capillary circuits. Also, 3D printers with co-print capability will enable
microfluidic chip fabrication with different materials to minimize self-fluorescence and enhance
biocompatibility and heat conductivity. If this technology were to be commercialized, the 3D
printing technology likely would need to be replaced with high throughput manufacturing such as
injection molding or embossing.
My numerical simulations provided insights to chip operation. I implemented a model to
simulate the RPA reaction in the presence of advection and diffusion. Similar models for LAMP
do not yet exist. The availability of LAMP simulators would enable a more complete analysis of
chip performance.
In the future, the smartphone can be integrated with appropriate optical filters to replace
the external fluorescence camera and reduce equipment costs. The Android application has great
potential for further development to guide the uninitiated user in performing the test, detect and
analyze signals from all reaction chambers concurrently, interpret test results for the patient, with
the patient’s permission report the results to the patient’s physician and public health officials, and
provide counseling.
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